https://trial.medpath.com/news/372852faf3f8c0cf/eirion-therapeutics-launches-first-in-human-clinical-trial-for-et-02-a-novel-treatment-for-androgenic-alopecia 2024-07-01T22:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/cc0ddbf07365adb6/fda-approves-nypozi-filgrastim-txid-a-biosimilar-to-neupogen 2024-07-01T21:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/768be1ba1b9b2abb/novartis-ianalumab-advances-in-phase-3-trial-for-lupus-nephritis-as-cdsco-approves-protocol-amendment 2024-07-01T18:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/5de6902807c0acbe/springworks-therapeutics-completes-submission-of-new-drug-application-to-the-fda-for-mirdametinib-for-the-treatment-of-children-and-adults-with-nf1-pn 2024-07-01T06:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/71be4a805620a041/fda-approves-pyzchiva-ustekinumab-ttwe-a-biosimilar-to-stelara 2024-07-01T05:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/08d7257048907068/ai-and-data-analytics-could-reduce-clinical-trial-failure-rates-by-20-quanthealth-ceo-reports 2024-07-01T01:29:50+00:00 weekly 0.7 https://trial.medpath.com/news/093cf3655be6d3d7/biologics-for-chronic-rhinosinusitis-with-nasal-polyps-pubmed 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b256823fab1b896c/frontline-nivolumab-plus-ipilimumab-reduces 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5600838c1a043e02/new-zealand-patient-becomes-first-globally-to-receive-gene-therapy-for-facioscapulohumeral-muscular-dystrophy 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b4531d82a5c986ba/bionic-leg-makes-walking-quicker-and-easier-for-amputees-trial-shows-medical-research-the-guardian 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f10adca04a255e13/lynparza-and-imfinzi-combination-recommended-for-eu-approval-in-endometrial-cancer-treatment 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9a1b7a131f817dce/improving-clinical-trial-informed-consent-new-strategies-to-enhance-patient-understanding-and-trial-success 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5bd9c1537b854e3a/ivabradine-s-impact-on-heart-failure-with-reduced-ejection-fraction-a-systematic-review-and-meta-analysis 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/da4c8f8d7a194a7a/kalivir-immunotherapeutics-announces-fda-clearance-of-investigational-new-drug-ind-for-oncolytic-immunotherapy-vet3-tgi-for-solid-tumors 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0261c9a7f49b3dca/kashiv-biosciences-enters-into-exclusive-licensing-agreement-with 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5f422cf4bad309ac/fda-approves-tepylute-thiotepa-ready-to-dilute-injectable-formulation-to-treat-breast-cancer-and-ovarian-cancer 2024-06-28T22:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/4217a532b16a4e22/infection-risk-with-btk-inhibitors-low-new-cll-study-finds 2024-06-28T16:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/0d4b70bec828629b/study-reveals-multiple-barriers-limiting-biologic-access-for-psoriasis-patients 2024-06-28T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5221dc484a9117b6/drug-farm-receives-fda-ind-clearance-for-first-in-class-alpk1-inhibitor-df-003-in-rosah-syndrome 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4fe3edba5e5e473b/fda-grants-orphan-drug-status-to-spinogenix-s-spg601-for-fragile-x-syndrome 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/66b36b9bb2e14b8e/ema-recommends-non-renewal-of-authorisation-of-duchenne 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0e5ceb35de3e113f/anokion-reveals-promising-phase-1b-2-data-on-kan-101-for-celiac-disease 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e2748bf7315b79a7/epkinly-epcoritamab-bysp-approved-by-u-s-fda-for-patients-with-relapsed-or-refractory-r-r-follicular-lymphoma-fl 2024-06-27T04:06:09+00:00 weekly 0.7 https://trial.medpath.com/news/cc98f8d4878d0215/uk-and-denmark-approve-csl-s-hemgenix-gene-therapy-for-haemophilia-b-with-novel-reimbursement-models 2024-06-27T02:18:36+00:00 weekly 0.7 https://trial.medpath.com/news/01a81e823bcb1caa/phase-1-clinical-trial-underway-for-qtx3046-in-krasg12d-mutated-advanced-solid-tumors 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9a4df061b7de3f19/exosome-based-cancer-therapy-advances-from-cell-free-treatment-to-targeted-drug-delivery 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0a5eef8a927a9e67/reunion-neuroscience-advances-re104-psychedelic-treatment-for-postpartum-depression-with-103m-funding 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8a38c2be119c026b/slated-capricor-fda-meeting-to-focus-on-dmd-therapy-deramiocel 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/45e9b2dc99b81a70/huadong-medicine-reports-positive-phase-i-results-for-oral-glp-1-receptor-agonist-hdm1002 2024-06-26T13:10:47+00:00 weekly 0.7 https://trial.medpath.com/news/33fd03de9d2ea967/cybin-makes-significant-progress-in-mental-health-treatment-development 2024-06-26T12:30:32+00:00 weekly 0.7 https://trial.medpath.com/news/e6fae8de3750cf5a/encell-s-mesenchymal-stem-cell-therapy-shows-promise-in-first-in-human-trial-for-charcot-marie-tooth-disease 2024-06-26T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/479ac8c3abdaa0c0/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer 2024-06-26T04:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/47f6d1cf1f46dd77/verona-pharma-announces-us-fda-approval-of-ohtuvayretm-ensifentrine 2024-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1442b040ea7b8002/star-therapeutics-presents-clinical-data-for-vga039-a-subcutaneous 2024-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/27db47b0d90bdb88/industry-survey-reveals-healthcare-mistrust-as-major-barrier-to-clinical-trial-diversity 2024-06-25T22:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/d37b5189ddecdd58/abbvie-provides-u-s-regulatory-update-on-abbv-951-foscarbidopa-foslevodopa 2024-06-25T21:06:33+00:00 weekly 0.7 https://trial.medpath.com/news/b10f661e10f5cb3c/fda-accepts-brexpiprazole-sertraline-combination-for-ptsd-review-marking-first-potential-new-treatment-in-over-20-years 2024-06-25T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a6705aa5ba097f5e/askbio-advances-parkinson-s-disease-treatment-with-phase-2-trial-of-ab-1005-gene-therapy 2024-06-25T11:55:54+00:00 weekly 0.7 https://trial.medpath.com/news/72360b3d077886ab/generative-ai-poised-to-transform-clinical-trial-efficiency-with-40-faster-regulatory-submissions 2024-06-25T03:29:52+00:00 weekly 0.7 https://trial.medpath.com/news/ae1a943fd51e1a2a/ionis-announces-olezarsen-new-drug-application-accepted-for-priority-review-and-enrollment-in-phase-3-shtg-program-completed 2024-06-25T01:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/0bf3c9efd5c199f2/riliprubart-shows-promise-as-first-in-class-treatment-for-chronic-inflammatory-demyelinating-polyneuropathy 2024-06-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/36d9150f96b1f7ab/n-power-medicine-secures-series-b-funding-to-enhance-oncology-clinical-trials-access 2024-06-24T16:54:32+00:00 weekly 0.7 https://trial.medpath.com/news/ceb9dbf2107f64f1/wegovy-helped-women-lose-more-weight-than-men-with-the-same-heart-condition-study-says 2024-06-24T14:42:00+00:00 weekly 0.7 https://trial.medpath.com/news/c397f069d08eaad5/sen-jam-pharmaceutical-completes-enrollment-for-phase-2-upper-respiratory-infection-covid-therapeutic 2024-06-24T13:56:03+00:00 weekly 0.7 https://trial.medpath.com/news/2c970ea608c35161/semaglutide-reduces-kidney-disease-risk-by-24-in-landmark-flow-trial-for-type-2-diabetes-patients 2024-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3595efcff9666b46/roche-announces-ema-has-initiated-review-of-the-elevidys 2024-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e3e371fecf8c9834/recursion-gives-guidance-on-seven-clinical-readouts-within-18-months 2024-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5eeb9c994f321e74/next-generation-obesity-drugs-target-muscle-preservation-and-enhanced-efficacy-beyond-glp-1-mechanisms 2024-06-23T17:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/ecb56aff840df891/inhale-3-trial-shows-inhaled-insulin-improves-glycemic-control-in-type-1-diabetes-patients 2024-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a8ed84709ff58183/keytruda-receives-40th-fda-approval-for-advanced-endometrial-cancer-treatment 2024-06-21T17:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/3a889be0ccb98f8b/fda-advisory-panel-unanimously-recommends-approval-of-lilly-s-alzheimer-s-drug-donanemab 2024-06-21T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/c5964c1ef065cd48/innocare-advances-dual-regulatory-milestones-with-tafasitamab-bla-acceptance-and-bcl2-inhibitor-icp-248-clinical-trial-approval-in-china 2024-06-21T09:56:48+00:00 weekly 0.7 https://trial.medpath.com/news/5b185f4737887f10/fda-approves-vyvgart-hytrulo-for-chronic-inflammatory-demyelinating-polyneuropathy 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9d97695f6e7148dc/vertex-s-vx-880-stem-cell-therapy-achieves-insulin-independence-in-type-1-diabetes-patients 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/54db78f615fd29c5/ultragenyx-intends-to-seek-accelerated-approval-for-mpsiii 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/afbe25fc193ea2b9/sarepta-surges-on-expanded-approval-of-muscular-dystrophy-drug 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6e34a239fa6d2e96/rapafusyn-pharmaceuticals-raises-28-million-series-a-to-advance-non-degrading-molecular-glue-platform 2024-06-20T18:23:01+00:00 weekly 0.7 https://trial.medpath.com/news/7a926d1862512709/cocrystal-pharma-s-cc-42344-shows-activity-against-h5n1-avian-influenza-in-preclinical-studies 2024-06-20T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/205b057cee99852b/ionctura-secures-eur80-million-series-b-to-advance-pi3kd-cancer-therapy-through-phase-ii-trials 2024-06-20T02:03:00+00:00 weekly 0.7 https://trial.medpath.com/news/b4e3c4805397b2df/sarepta-wins-full-approval-and-label-expansion-for-dmd-gene-therapy-biospace 2024-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7616737b89528522/open-surgery-outperforms-minimally-invasive-techniques-in-cervical-cancer-treatment-study-finds 2024-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2ad7d25251784f87/paxlovid-reduces-risk-of-long-covid-and-post-acute-hospitalization-or-death-in-high-risk-patients 2024-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fc9fadb75035db3d/ruxolitinib-maintains-clinical-benefit-in-myelofibrosis-patients-despite-treatment-related-anemia 2024-06-19T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/21a23cca8492e5a2/pfizer-explores-brentuximab-vedotin-for-systemic-sclerosis-treatment-in-development-pipeline 2024-06-19T09:28:16+00:00 weekly 0.7 https://trial.medpath.com/news/1cd1e78ebdde9ea5/ai-powered-blood-test-shows-promise-for-early-parkinson-s-detection-with-100-accuracy 2024-06-19T02:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/a826a317bc617fc5/kymera-therapeutics-reveals-new-phase-1-trial-data-for-kt-333-patsnap 2024-06-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a3712423ffc6bf5c/a-report-from-the-children-s-oncology-group-new-agents 2024-06-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/775a16b0d6ecc8c5/fda-extends-review-timeline-for-regenxbio-s-hunter-syndrome-gene-therapy-rgx-121 2024-06-18T07:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/c443fccb8aa145d6/cll-patients-prioritize-pfs-benefits-in-treatment-choices-survey-reveals 2024-06-18T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8021076c37b4e965/novel-nav1-8-inhibitors-lead-wave-of-non-opioid-pain-treatments-as-industry-tackles-opioid-crisis 2024-06-18T04:41:49+00:00 weekly 0.7 https://trial.medpath.com/news/1efcab0e6376b70c/fda-approves-roche-s-ventana-dp-200-digital-pathology-platform-for-clinical-diagnosis 2024-06-18T01:28:59+00:00 weekly 0.7 https://trial.medpath.com/news/9c2e01f421a37d87/kalvista-submits-new-drug-application-to-fda-for-sebetralstat-as-first-oral-on-demand-treatment-for-hereditary-angioedema 2024-06-18T00:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/a726f8a5ffb0c968/three-rsv-vaccines-now-available-for-older-adults-as-fda-approves-moderna-s-mresvia 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/812b4669a92db206/u-s-fda-approves-skyrizi-r-risankizumab-rzaa-for-ulcerative-colitis 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c5f4984e1da9c722/acadia-pharmaceuticals-presents-real-world-data-on-daybuetm-trofinetide-for-rett-syndrome 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/686b68ac5ab729f6/arch-biopartners-receives-ethics-approval-for-phase-ii-trial-of-lsalt-peptide-in-calgary 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/563864636eb1198d/johnson-johnson-submits-bla-to-fda-for-lung-cancer-drug 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4ebb2cfc475ce835/clinical-trials-in-2024-a-preview-of-trials-planned-to-initiate 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd93cb9779dde61b/cerevel-therapeutics-advances-emraclidine-development-for-alzheimer-s-related-dementia-and-psychosis 2024-06-17T21:52:12+00:00 weekly 0.7 https://trial.medpath.com/news/90d6005212e47aab/zanubrutinib-combination-therapies-show-promise-in-high-risk-cll-sll-treatment 2024-06-17T20:09:48+00:00 weekly 0.7 https://trial.medpath.com/news/f02bc55cd7e5f1aa/fda-approves-merck-s-capvaxive-first-21-serotype-pneumococcal-vaccine-designed-specifically-for-adults 2024-06-17T17:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/4ea1f221bae0ac7a/regeneron-s-lynozyfic-receives-fda-approval-for-multiple-myeloma-with-70-response-rate 2024-06-17T08:32:32+00:00 weekly 0.7 https://trial.medpath.com/news/6fb5d7939495bb10/merck-s-keytruda-advances-development-program-for-hepatocellular-carcinoma-treatment 2024-06-17T07:59:02+00:00 weekly 0.7 https://trial.medpath.com/news/41a3c4f4f026d7c2/pharmamar-s-trabectedin-expands-development-portfolio-with-multiple-cancer-indications 2024-06-17T07:42:59+00:00 weekly 0.7 https://trial.medpath.com/news/a412725968015429/roche-s-bevacizumab-under-evaluation-for-endometrial-cancer-treatment 2024-06-17T07:41:47+00:00 weekly 0.7 https://trial.medpath.com/news/753c0402d3da82cc/argenx-to-unveil-vision-2030-and-share-updates-on-clinical-pipeline-at-r-d-day 2024-06-17T05:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/9ff573e5fa3b311a/car-t-cell-therapy-shows-promising-results-in-lupus-and-autoimmune-diseases-at-eular-conference 2024-06-17T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9b55c5bb14067e96/avicursen-by-percheron-therapeutics-for-duchenne-muscular-dystrophy 2024-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fb34a53bf39ad53a/kite-s-yescarta-shows-superior-manufacturing-success-and-t-cell-performance-in-second-line-treatment-of-large-b-cell-lymphoma 2024-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6469f451c7d763b5/mendus-reports-promising-long-term-survival-data-for-vididencel-in-acute-myeloid-leukemia 2024-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/79c1510bee32435b/calquence-plus-chemoimmunotherapy-shows-27-reduction-in-disease-progression-risk-for-untreated-mantle-cell-lymphoma 2024-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/11433a49fa181e66/nih-s-novel-five-drug-combination-shows-promise-for-relapsed-aggressive-b-cell-lymphoma 2024-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c2349383a923d645/iaso-bio-s-car-t-therapy-shows-100-response-rate-in-high-risk-newly-diagnosed-multiple-myeloma-patients 2024-06-15T10:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/ccf1336db786dfa9/roche-s-columvi-demonstrates-41-reduction-in-death-risk-in-phase-iii-dlbcl-trial 2024-06-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1e8faf3e82e5fbee/disitamab-vedotin-plus-toripalimab-shows-early-efficacy-in-her2-positive-mibc 2024-06-14T19:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/9f4b81ed7030a397/liso-cel-car-t-therapy-shows-promising-results-across-multiple-lymphoma-subtypes 2024-06-14T18:03:33+00:00 weekly 0.7 https://trial.medpath.com/news/fcb09cf6a1d00a4b/disc-medicine-presents-positive-clinical-data-across-portfolio 2024-06-14T11:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/1f7e1496c42aa089/deadline-approaching-for-transitioning-clinical-trials-from-ctd-to-ctr 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a1211148f278554b/lixte-biotechnology-inks-deal-for-cancer-drug-trial 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dbd800b27de34e42/blood-stage-malaria-vaccine-candidate-rh5-1-matrix-m-trial-in-tanzania 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7003326181cd6d9c/neoadjuvant-camrelizumab-an-anti-pd-1-antibody-plus-chemotherapy-or 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dd54897b51c85efe/fda-approves-blinatumomab-for-cd19-b-all-in-the 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dc513233e93db287/xeltis-axess-restorative-conduit-to-be-studied-in-fda-ide-pivotal-trial 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1ac0c859a948fc5b/ugn-102-demonstrates-long-term-durability-in-nmibc 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9a3a938afd4c93f1/pfizer-phase-iii-dmd-gene-therapy-study-misses-goal-pfizer-nyse-pfe-capricor-therapeutics-nasdaq-capr-benzinga 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b1c946f69a9ee83e/urogen-pharmas-promising-trial-results-and-fda-progress-tipranks-com 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2172cc9b5ab7134f/why-fda-panel-rejected-mdma-therapy-and-whats-next-for-psychedelic-medicine 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/736b8621eac6083a/formycon-advances-phase-iii-trial-for-keytruda-biosimilar-fyb206-in-non-small-cell-lung-cancer 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4ca1b70192ac14c1/urogen-pharma-holds-steady-promising-ugn-102-results-balanced-with-market-caution-markets-insider 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/769d9d60383212bc/fda-grants-breakthrough-therapy-designation-to-oac-therapy-for-myotonic-dystrophy-type-1 2024-06-12T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7077c928fb0ed1de/swimming-microrobots-deliver-cancer-fighting-drugs-to-metastatic-lung-tumors-in-mice 2024-06-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4d6a22c09fcf69db/meta-analysis-confirms-efficacy-and-safety-of-antibody-drug-conjugates-in-advanced-urothelial-carcinoma-treatment 2024-06-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/06c06f3c9387c5fc/positive-phase-2-results-for-setrusumab-in-osteogenesis-imperfecta-treatment 2024-06-11T21:47:59+00:00 weekly 0.7 https://trial.medpath.com/news/b327136d617c77aa/eha-2024-monoclonal-antibodies-continue-to-dominate-multiple-myeloma-treatments 2024-06-11T17:11:25+00:00 weekly 0.7 https://trial.medpath.com/news/3638f373e03f30fe/aldeyra-therapeutics-concludes-subject-enrolment-in-dry-eye-disease-trial 2024-06-11T12:58:37+00:00 weekly 0.7 https://trial.medpath.com/news/5dbeffde5b752c5d/what-s-going-on-with-mid-cap-cancer-focused-verastem-oncology-stock-on-friday 2024-06-11T12:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/c5d488ba0ab9c683/gsk-s-rsv-vaccine-arexvy-gets-fda-nod-for-adults-50-59-years 2024-06-11T12:49:50+00:00 weekly 0.7 https://trial.medpath.com/news/d97b9b3c41b56bd3/moderna-wins-fda-approval-for-rsv-vaccine 2024-06-11T12:49:50+00:00 weekly 0.7 https://trial.medpath.com/news/19dae1991e5b7065/trial-of-hormonal-gel-shows-promise-for-male-birth-control 2024-06-11T12:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/f0095e407b832866/moonlake-immunotherapeutics-initiates-phase-3-vela-program-for-sonelokimab-in-hidradenitis-suppurativa-treatment 2024-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bbae84c41d374b9d/study-reveals-impact-of-cholesterol-changes-on-cardiovascular-disease-risk 2024-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2da76c0d609352b1/three-promising-drugs-for-treating-alzheimer-s-disease-bring-fresh-hope 2024-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/286c1f783291c12e/upadacitinib-outperforms-dupilumab-in-landmark-level-up-trial-for-moderate-to-severe-atopic-dermatitis 2024-06-10T21:35:51+00:00 weekly 0.7 https://trial.medpath.com/news/f9b290eb79257ac5/moderna-s-combination-flu-covid-vaccine-shows-superior-immune-response-in-phase-3-trial 2024-06-10T16:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/d9f30e4b3feca691/leqembi-s-slow-adoption-challenges-and-progress-in-alzheimer-s-treatment 2024-06-10T09:00:35+00:00 weekly 0.7 https://trial.medpath.com/news/f4d6d0763563aa69/can-fite-receives-irb-approval-for-phase-iia-pancreatic-cancer-trial-of-namodenoson 2024-06-10T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7b36d085807099e2/ipsen-s-iqirvo-receives-u-s-fda-accelerated-approval-for-primary-biliary-cholangitis-treatment 2024-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f74ac75a7dc1e277/clinical-and-radiographic-evaluation-of-mineral-trioxide-aggregate-and-human-amniotic-membrane-in-primary-molar-teeth 2024-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/213cec344f6c3f5f/fda-accepts-eisai-s-filing-of-leqembi-r-for-alzheimer-s-disease-treatment 2024-06-09T23:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/3855d69605c8a161/concierge-medicine-market-set-to-reach-10-9-billion-by-2032-amid-growing-healthcare-disparities 2024-06-07T02:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/d27f8393c182b5fe/petros-pharmaceuticals-completes-ai-integrated-study-for 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/288554a860a38890/fda-approves-rytelotm-imetelstat-for-lower-risk-mds-with-transfusion-dependent-anemia 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1b6a672d1c778583/fda-approves-geron-s-treatment-for-lower-risk-mds-blood-cancer-by-investing-com 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/020afb09b2a030e9/this-pharma-stock-dropped-60-premarket-as-fda-halted-diabetes-drug-trials-biomea-fusion-nasdaq-bmea-benzinga 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/236e794a1ce7e63d/dual-agonist-drug-survodutide-shows-promise-in-phase-2-trial-for-fatty-liver-disease-treatment 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d3af2ab0115729a2/maia-biotechnology-shares-rise-after-fda-s-telomerase-inhibitor 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/641a806557b0f5fe/abbvie-s-abbv-ovarian-cancer-therapy-meets-study-goal 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2754e7a9f28161b6/abu-dhabi-health-department-and-novartis-partner-to-advance-genomics-research-and-radioligand-therapy 2024-06-06T22:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/17b0ddd84f1704bc/fda-rescinds-marketing-ban-on-juul-vaping-products-returns-applications-to-review-status 2024-06-06T17:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/7f0fd3436569a1bf/bridgebio-oncology-therapeutics-announces-first-patient-dosed-with-bbo-8520-in-the-onkoras-101-trial-for-krasg12c-nsclc 2024-06-06T15:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/e1bf69b0ead25c4f/cilcare-and-shionogi-form-eur400-million-partnership-to-develop-novel-hearing-loss-treatments 2024-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fe795bf88e6b6f3f/sequana-medical-to-present-alfapump-r-safety-and-quality-of-life-data-at-easl-congress-2024 2024-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4f81b72065a36756/maia-biotechnology-announces-year-to-date-achievements-and-highlights 2024-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9c87e5fec2e4c903/fda-advisory-panel-unanimously-recommends-jn-1-targeted-covid-19-vaccines-for-fall-2024 2024-06-05T21:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/4c67e87dcdf6578b/bilateral-gene-therapy-restores-hearing-in-both-ears-for-children-with-inherited-deafness 2024-06-05T09:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/247757361fc10328/inhibikase-therapeutics-completes-enrollment-in-phase-2-trial-for-parkinson-s-disease-treatment 2024-06-05T08:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/8e15b026328f6e9b/streamlining-clinical-trials-in-finland-s-unique-environment 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1324a1cde1e0b62f/acelyrin-inc-announces-positive-16-week-data-from-its-global-phase-2b-3-trial-of-izokibep-in-psoriatic-arthritis-to-be-shared-during-late-breaking-oral-presentation-at-eular-2024-biospace 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2094974502a35f5c/asco24-j-j-innovative-medicine-touts-positive-multiple-myeloma-drug-data 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3b0b88f09c3547a2/relay-therapeutics-announces-clinical-trial-collaboration-with-pfizer-to-evaluate-atirmociclib-in-combination-with-rly-2608 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/67f254a020a8d3a5/ipsen-s-elafibranor-demonstrates-sustained-efficacy-in-primary-biliary-cholangitis-phase-iii-trial 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a074a7d7b3ad1b3b/eli-lilly-to-expand-pain-portfolio-with-siteone-acquisition 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/574cf2a07137c1c2/glp-1-weight-loss-drugs-like-ozempic-show-promising-cancer-prevention-benefits 2024-06-04T17:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/e4ca451df8902623/takeda-s-tak-861-shows-promising-results-in-phase-2b-trial-for-narcolepsy-type-1 2024-06-04T13:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/ec9281ec8269ac89/u-s-clinical-trials-begin-for-twice-yearly-hiv-prevention-injection 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9622178e2b81ebcd/capricor-therapeutics-announces-positive-3-year-efficacy 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f56033f9b86ce0a3/glycomimetics-announces-comprehensive-results-from-pivotal-phase-3-study-of-uproleselan-in-relapsed-refractory-r-r-acute-myeloid-leukemia-aml 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8de7bb755180dc02/carsgen-s-satri-cel-shows-promise-in-phase-1-trial-for-gastrointestinal-cancers 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d605d5016d337cd5/ad109-advances-to-phase-iii-trials-as-first-oral-therapy-for-obstructive-sleep-apnea 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/214fca22764b2455/sanofi-highlights-phase-3-sarclisa-data-in-multiple-myeloma-treatment 2024-06-03T20:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/f423da045eb1636a/new-trial-data-shows-enhertu-reduces-breast-cancer-progression-risk-by-38-as-access-remains-denied-in-england 2024-06-03T16:51:13+00:00 weekly 0.7 https://trial.medpath.com/news/56e1fe48e2412c3e/crinetics-reports-promising-results-for-atumelnant-in-treating-cah-and-acth-dependent-cushings-syndrome 2024-06-03T16:06:05+00:00 weekly 0.7 https://trial.medpath.com/news/30ead848e102b8f4/bispecific-antibodies-show-promise-in-multiple-myeloma-treatment-across-different-patient-populations 2024-06-03T15:18:07+00:00 weekly 0.7 https://trial.medpath.com/news/6d49ab86a0609395/structure-s-obesity-pill-shows-promising-weight-loss-results-in-study 2024-06-03T12:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/fff0dc60d312b4c7/phase-3-data-shows-mirikizumab-s-efficacy-in-crohn-s-disease-treatment 2024-06-03T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ca9135695b50e91b/eledon-s-tegoprubart-shows-superior-kidney-function-preservation-in-phase-1b-transplant-trial 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fe22e4dbd745aca8/qiagen-launches-qiastat-dx-gastrointestinal-panel-2-in-the-u-s-for-improved-gi-infection-diagnosis 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3db455cedca9886e/mid-stage-trial-failure-for-sanofi-and-denali-s-als-drug 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9adac0742c1bad82/transgene-advances-personalized-cancer-vaccine-tg4050-to-phase-ii-trial-in-head-and-neck-cancer 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a756d3a12cea533a/stealth-biotherapeutics-announces-fda-acceptance-of-new-drug 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1ec9823c636a5c74/tagrisso-demonstrates-84-reduction-in-disease-progression-risk-for-egfr-mutated-stage-3-nsclc 2024-06-02T12:00:42+00:00 weekly 0.7 https://trial.medpath.com/news/cd0071df9620c962/leqembi-launches-in-austria-and-germany-as-first-anti-amyloid-alzheimer-s-therapy-in-eu 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7f2e51f11ad42a84/impact-biotech-reports-77-complete-response-rate-for-padeliporfin-vtp-in-low-grade-upper-tract-urothelial-cancer 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4c61ec68a1bfe06c/merck-s-keytruda-shows-promise-in-platinum-resistant-ovarian-cancer-trial 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e51abe5985866241/chime-mabgeek-achieve-phase-iii-milestone-with-mg-k10 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/679b8772ab655a81/sandoz-launches-first-ustekinumab-biosimilar-autoinjector-in-europe-with-pyzchiva 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/79b9d61042e02e08/caribou-biosciences-reports-positive-clinical-data-from-cb-010-antler-phase-1-trial 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bc65e0257cca629c/bio-thera-s-bat8006-shows-promising-37-response-rate-in-platinum-resistant-ovarian-cancer-phase-i-trial 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5b52e9afc80dc142/newron-myung-collaborate-for-evenamide-development-in-south-korea 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/39164733d9d5ba2d/intellia-s-crispr-gene-therapy-shows-potential-as-functional-cure-for-hereditary-angioedema-in-long-term-study 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3a15c98fada526f9/first-line-camrelizumab-plus-rivoceranib-maintains-survival-onclive 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/425c58d9fd1c3f1d/2024-san-antonio-breast-cancer-symposium 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/feddb04bc9e94cc7/ultra-sensitive-blood-test-predicts-breast-cancer-recurrence-up-to-41-months-before-clinical-symptoms 2024-06-01T23:01:15+00:00 weekly 0.7 https://trial.medpath.com/news/c92577c20fbfb15c/subcutaneous-amivantamab-demonstrates-superior-outcomes-over-iv-administration-in-egfr-mutated-nsclc 2024-06-01T18:55:48+00:00 weekly 0.7 https://trial.medpath.com/news/cf7922ace3808600/inflarx-s-gohibic-vilobelimab-selected-for-first-barda-sponsored-clinical-trial 2024-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e6743c0a41261eba/amivantamab-plus-lazertinib-improves-pfs-irrespective-of 2024-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ebc0cd9f87d441ad/asco-2024-highlights-breakthroughs-in-cancer-treatment 2024-05-31T15:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/2375c7d2c7f94508/iterum-therapeutics-receives-fda-acceptance-of-resubmission-of-nda-for-oral-sulopenem-for-the-treatment-of-uncomplicated-urinary-tract-infections 2024-05-31T02:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/79ad2ed189ce77e2/novartis-scemblix-r-phase-iii-data-first-to-show-superior-efficacy-with-a-favorable-safety-and-tolerability-profile-vs-standard-of-care-tkis-in-adults-with-newly-diagnosed-cml-novartis 2024-05-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e9ffb95df244fedb/strand-therapeutics-doses-first-patient-with-programmable-mrna-cancer-therapy-stx-001-in-phase-1-trial 2024-05-30T11:36:06+00:00 weekly 0.7 https://trial.medpath.com/news/e5fb80e95d0c4d10/fda-grants-regenerative-medicine-advanced-therapy-designation-to-bemdaneprocel-for-parkinsons-disease 2024-05-30T09:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/257fd0cc601eb74b/breakthroughs-and-trends-in-anti-obesity-drug-development-for-2024 2024-05-30T06:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/adcda92cfd4386be/u-s-fda-acknowledges-astellas-resubmission-of-biologics-license-application-for-zolbetuximab-and-sets-new-action-date 2024-05-30T05:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/c28fedf06165d963/nrx-101-shows-promise-as-first-antidepressant-to-reduce-suicidality-in-bipolar-depression 2024-05-29T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f9a1357acf7334e0/passage-bio-advances-in-clinical-trial-for-genetic-ftd-treatment 2024-05-29T09:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/5b021b5256b39cdd/cellectar-biosciences-partners-with-city-of-hope-cancer-center-for-iopofosine-clinical-development 2024-05-29T06:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/db25621e570544ff/milestone-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-cardamyst 2024-05-29T02:05:34+00:00 weekly 0.7 https://trial.medpath.com/news/3b5cdae40566ccc0/fda-grants-priority-review-to-roches-inavolisib-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation 2024-05-29T02:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/7a530c4d0f1e438d/acelyrin-inc-announces-lonigutamab-phase-1-2-proof-of-concept-data-to-be-shared-during-late-breaking-oral-presentation-at-endo-2024-marketscreener 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a2329a9239b0239a/extended-daratumumab-krd-therapy-achieves-85-three-year-pfs-in-newly-diagnosed-multiple-myeloma-without-transplant 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c76a9a1223894d3b/dr-landgren-on-the-utility-of-mrd-as-an-end-point-in 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/db12dac27592da84/foundation-medicine-and-pmv-pharma-partner-to-develop-companion-diagnostic-for-rezatapopt 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c61ab068a4e3003a/nanoviricides-develops-first-in-class-broad-spectrum-antiviral-agent-nv-387 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a3d22ee36ad708d5/cdc-clinical-guidelines-on-the-use-of-doxycycline 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4aa7aa0d73e37c68/spineart-receives-fda-510-k-clearance-for-scarlet-ac-ti-anterior-cervical-cage-with-advanced-ti-life-technology 2024-05-28T15:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/2d63d334691170ad/fda-grants-accelerated-approval-to-krazati-plus-cetuximab-for-kras-g12c-mutated-colorectal-cancer 2024-05-28T14:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/480897dee074de4e/j-j-expands-portfolio-with-1-25b-acquisition-of-skin-disease-medicine 2024-05-28T10:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/1bab514d564adadb/resminostat-s-approval-by-the-ema-and-the-fda-mhra-and-more-how 2024-05-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/203e9650b34613db/rosacea-pipeline-analysis-2024-insights-into-therapeutics-development 2024-05-27T18:55:52+00:00 weekly 0.7 https://trial.medpath.com/news/e97f9d63c4f5136c/remegen-s-telitacicept-receives-priority-review-for-myasthenia-gravis-treatment-following-successful-phase-iii-trial 2024-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e8242f24339521cb/pneumagen-s-neumifil-shows-promising-results-in-phase-2-influenza-prevention-trial 2024-05-24T16:59:01+00:00 weekly 0.7 https://trial.medpath.com/news/e738d2ff4c1dcb82/ema-validates-marketing-applications-for-hlx14-denosumab-biosimilar-in-osteoporosis-treatment 2024-05-24T10:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/7a30af92004a7a23/ai-driven-drug-discovery-accelerates-with-new-academic-alliance-targeting-protein-kinases 2024-05-23T14:29:16+00:00 weekly 0.7 https://trial.medpath.com/news/dcf30fad006c78ba/fda-grants-fast-track-designation-to-vcn-01-for-metastatic-pancreatic-cancer-treatment 2024-05-23T14:27:08+00:00 weekly 0.7 https://trial.medpath.com/news/0780362a9af0bbc9/eyp-1901-shows-promise-in-reducing-treatment-burden-for-wet-amd-patients-in-phase-2-davio-2-trial 2024-05-23T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e71de69cd6fe940e/vir-biotechnology-to-present-latest-hepatitis-delta-and-b-data-at-easl-congress-2024 2024-05-22T12:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/f05734f989c1cdba/biogen-expands-into-immunology-with-acquisition-of-hi-bio 2024-05-22T11:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/7e1ebb0a2f0dda13/can-ai-predict-the-development-of-autoimmune-diseases 2024-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/78e527ab068b59ac/sequana-medical-announces-positive-fda-meeting-outcome-for-alfapump-pma-application 2024-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f2632565309ebc5f/home-immix-biopharma-inc 2024-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e1fdbf47f3431885/henlius-to-present-latest-clinical-data-of-hlx22-at-2024-esmo-gastrointestinal-cancers-congress 2024-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6f9dbf77d8ba3e1a/fda-clears-path-for-cingulate-s-ctx-1301-adhd-treatment-nda-submission 2024-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5eb050e4d72aab66/study-highlights-efficacy-and-safety-of-sglt2-inhibitors-in-type-2-diabetes-management 2024-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e960654fafc3b6f3/atara-biotherapeutics-submits-tabelecleucel-tab-cel-r-biologics-license-application-for-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-with-u-s-fda 2024-05-20T23:05:54+00:00 weekly 0.7 https://trial.medpath.com/news/0d20bf3e614c5590/spinogenix-receives-fda-orphan-drug-designation-for-spg601-to-treat-fragile-x-syndrome 2024-05-20T13:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/4487529b81b950c7/hiv-vaccine-breakthrough-new-candidate-successfully-generates-broadly-neutralizing-antibodies 2024-05-20T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6d7002970cae59ef/anokion-announces-promising-clinical-data-for-kan-101-in-celiac-disease-treatment 2024-05-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/092c379376ecef71/neuralink-gets-fda-approval-for-second-brain-implant-patient-wsj 2024-05-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6fd3078b17fec0f2/bayer-s-non-hormonal-therapy-shows-promise-in-reducing-hot-flashes-in-phase-iii-trials 2024-05-17T11:13:54+00:00 weekly 0.7 https://trial.medpath.com/news/d540933fd0a68689/progress-in-sclc-from-deadly-to-cure 2024-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5df2e177780102b9/maternal-vaccine-trials-face-critical-challenges-only-6-of-late-stage-studies-include-pregnant-women 2024-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ea7699fbd8d5ca60/eli-lilly-s-once-weekly-insulin-efsitora-demonstrates-non-inferior-efficacy-in-phase-3-trials-for-type-2-diabetes 2024-05-16T17:55:22+00:00 weekly 0.7 https://trial.medpath.com/news/cf4e06cf5037204c/south-rampart-pharma-s-srp-001-shows-promise-as-non-opioid-pain-treatment-in-phase-1-trial 2024-05-16T10:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/cf418f674e2c31a6/investors-launch-400m-hercules-startup-to-develop-novel-glp-1-therapies-for-obesity-and-diabetes 2024-05-16T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/eed03c409d570d74/lsu-health-new-orleans-develops-novel-non-addictive-painkiller-with-fda-fast-track-designation 2024-05-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1a41d9abcbffe083/fda-approves-amgen-s-treatment-for-most-deadly-form-of-lung-cancer 2024-05-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/be97c018613ac322/optilume-bph-catheter-system-preserves-sexual-function-while-treating-luts 2024-05-15T19:30:39+00:00 weekly 0.7 https://trial.medpath.com/news/48546d41b4ec92e5/south-korea-accelerates-drug-reimbursement-process-with-new-pilot-program 2024-05-15T11:22:25+00:00 weekly 0.7 https://trial.medpath.com/news/2b0a5793ea06a1d6/pioneering-immunotherapy-approach-keeps-brain-cancer-at-bay-for-australian-doctor-who-helped-develop-it 2024-05-15T06:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/2fd1d84d90eba12a/outlook-therapeutics-advances-ons-5010-toward-potential-first-approved-ophthalmic-bevacizumab-for-retinal-diseases 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bf0f64736d4a3b05/study-of-tecovirimat-for-human-mpox-virus-stomp 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1dc96d6ed24d2fdf/blackstone-launches-uniquity-bio-with-300m-to-advance-anti-tslp-therapy-for-asthma-and-copd 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d5c9807beb095e29/fda-approves-hpv-self-collection-for-cervical-cancer-screening-expanding-access-to-early-detection 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4fb884be9b9c1b24/maat-pharma-announces-global-offering-to-fund-microbiome-ecosystem-therapies-development 2024-05-14T16:01:27+00:00 weekly 0.7 https://trial.medpath.com/news/df0f2262aa8e5fd9/ryvu-therapeutics-to-present-promising-rvu120-and-synthetic-lethality-data-at-major-oncology-conferences 2024-05-14T15:39:44+00:00 weekly 0.7 https://trial.medpath.com/news/fc538daef6fb3656/fda-clears-ind-application-for-synkir-310-trial-in-relapsed-refractory-b-nhl 2024-05-14T13:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/bdb4e042fc913795/xilio-therapeutics-advances-tumor-activated-immunotherapy-pipeline-with-phase-2-trial-of-xtx101-set-for-q3-2024 2024-05-14T11:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/47e1ed76c64719be/ascendis-pharma-announces-extension-of-u-s-food-and-drug-administration-review-period-for-transcon-pth-for-adults-with-hypoparathyroidism 2024-05-14T01:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/e8277c39d17e9b4e/nyxoah-s-genio-system-shows-strong-results-in-dream-pivotal-study-for-obstructive-sleep-apnea-treatment 2024-05-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6591ec089d66a2d6/nanoviricides-ceo-discusses-nv-387-s-broad-spectrum 2024-05-13T15:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/f42f3882433ac92a/fda-grants-fast-track-designation-to-snb-101-for-small-cell-lung-cancer-treatment 2024-05-13T14:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/3e815c3446bc345b/plant-virus-nanoparticles-show-broad-protection-against-metastatic-cancers-in-preclinical-studies 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/70cb54498a086077/urogen-pharma-announces-date-for-envision-data-new-long-term-jelmyto-durability-data-and-reports-2024-first-quarter-financial-results-and-business-highlights 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3ccb2d5dd3bfbf68/what-the-results-of-wegovys-longest-clinical-trial-yet-show-about-weight-loss-side-effects-and-heart-protection-cnn 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3c4bb0424e3e7020/merck-provides-update-on-phase-3-keyvibe-010-trial-evaluating-an 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/835517062c2f3121/ai-clinical-trial-to-treat-depression-in-oxford-university-study 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/230419dd0781d2c6/sumitomo-pharma-announces-fda-acceptance-of-supplemental-new-drug 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/68401d3b8ddd5271/moleculin-reports-first-quarter-2024-financial-results-and-corporate-update 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6ad2700faba17feb/kite-and-arcellx-prepare-to-launch-phase-iii-multiple-myeloma-trial 2024-05-12T17:11:25+00:00 weekly 0.7 https://trial.medpath.com/news/6fcdff59704741be/agenus-agen-q1-2024-earnings-call-transcript 2024-05-12T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/42f3ef80fd596d30/surprise-eli-lilly-is-racing-toward-yet-another-blockbuster 2024-05-12T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/81d758ab4dc16a2b/kymera-therapeutics-inc-kymr-q1-2024-earnings-call-transcript-highlights 2024-05-12T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/b777a9e209621e6e/what-s-going-on-with-dermatitis-focused-rapt-therapeutics-stock-on-thursday 2024-05-12T13:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/a15bc5847f1df0b1/rapt-therapeutics-inc-reports-q1-2024-earnings-a-detailed-financial-overview 2024-05-12T13:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/d887c51980ca92ac/fibrogen-inc-nasdaq-fgen-q1-2024-earnings-call-transcript 2024-05-12T13:01:21+00:00 weekly 0.7 https://trial.medpath.com/news/71163096a75e66eb/vertex-pharmaceuticals-incorporated-nasdaq-vrtx-q1-2024-earnings-call 2024-05-12T12:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/c0a9e1e723b12fd1/q1-2024-axsome-therapeutics-inc-earnings-call 2024-05-12T12:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/4a99f0250f7d6103/bristol-myers-bmy-fails-to-meet-goal-in-opdivo-nsclc-study 2024-05-12T12:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/0863bdafeb079b2d/dll3-guided-therapies-show-promise-in-small-cell-lung-cancer-treatment 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2b58925b46495238/pharmather-receives-fda-goal-date-of-october-29-2024-for-priority-ketamine-anda-approval 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/62d8e94a607e952a/efficacy-and-safety-of-piwei-peiyuan-prescription-in-treating-chronic-atrophic-gastritis 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5af2ed4581d517f9/recursion-provides-business-updates-and-reports-first 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/56dfc872912c814c/reflections-on-the-new-fda-clinical-pharmacology-guidance-for-antibody-drug-conjugates 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/68dbab1577ddafba/intellia-therapeutics-reports-first-quarter-2024-financial-results-and-operational-progress 2024-05-09T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/b97c293540bfce1d/acelyrin-inc-provides-business-update-and-highlights-key-upcoming-milestones 2024-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b3d8da1037faa0ab/know-labs-to-present-clinical-research-at-the-2024-american-association-of-clinical-endocrinology-annual-meeting 2024-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2d61b09a962da911/r3-vascular-secures-87-million-in-series-b-financing-and-appoints-new-ceo 2024-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/43413dd1e8b93af9/siren-biotechnology-partners-with-catalent-to-advance-aav-immuno-gene-therapies-for-cancer 2024-05-08T15:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/fd646689db171940/cel-sci-receives-fda-approval-for-confirmatory-study-of-multikine-in-head-and-neck-cancer-treatment 2024-05-08T13:16:06+00:00 weekly 0.7 https://trial.medpath.com/news/3f64aff1788b5afe/tivic-health-s-non-invasive-vagus-nerve-stimulation-shows-promising-results-in-clinical-trial 2024-05-08T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5f99c3e2163b0d8e/teva-and-medincell-announce-positive-phase-3-efficacy-results-for-tev-749-in-schizophrenia-treatment 2024-05-08T06:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/e8b9579f40629455/fda-approves-first-in-class-hiv-1-treatment 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1272e4d700d8ac0a/participants-of-pioneering-crispr-gene-editing-trial-see-vision 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8394f714235223d9/apple-watch-s-a-fib-history-cleared-by-fda-for-use-in-clinical-trials 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/642020b29a712bf9/arcturus-therapeutics-announces-first-quarter-2024-financial-update-and 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6100a21f3d53c55e/novartis-acquires-mariana-oncology-for-1-billion-to-strengthen-radioligand-therapy-pipeline 2024-05-07T10:47:37+00:00 weekly 0.7 https://trial.medpath.com/news/6a9d2637bf3ba148/denali-therapeutics-reports-first-quarter-2024-financial 2024-05-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3cb9ba713a59b252/repare-therapeutics-provides-business-and-clinical-update-and-reports-first-quarter-2024-financial-results 2024-05-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/981788c779104412/d3s-001-shows-superior-kras-g12c-inhibition-with-rapid-target-engagement-and-promising-clinical-activity 2024-05-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d083456eb1d0411b/recce-pharmaceuticals-secures-final-china-patent-for-synthetic-anti-infectives-completing-global-protection-until-2035 2024-05-06T23:47:40+00:00 weekly 0.7 https://trial.medpath.com/news/86121aba23c54d61/fda-approves-colosense-first-rna-based-noninvasive-colorectal-cancer-screening-test 2024-05-06T14:50:45+00:00 weekly 0.7 https://trial.medpath.com/news/198d7fd6f89883a7/cybin-inc-advances-psychedelic-treatments-for-mental-health 2024-05-06T13:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/628d0d3f7425d243/lyra-therapeutics-phase-3-enlighten-1-trial-for-chronic-rhinosinusitis-treatment-fails-to-meet-primary-endpoint 2024-05-06T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/e9d50c1c7f8447d2/mediar-therapeutics-advances-fibrosis-treatment-with-phase-1-trial-of-mtx-463 2024-05-06T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/934d623bfc4fe233/idt-australia-secures-victorian-government-grant-to-establish-nation-s-first-commercial-adc-manufacturing-facility 2024-05-06T02:48:51+00:00 weekly 0.7 https://trial.medpath.com/news/c75bf970ade29fbf/systematic-review-of-phase-ii-and-iii-clinical-trials-for-relapsing-multiple-sclerosis 2024-05-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5b5b2597decebdfe/off-the-shelf-allogeneic-car-t-therapies-show-promise-for-b-cell-malignancies 2024-05-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/845670cac72769a8/urogen-announces-results-from-atlas-showing-robust-ugn-102-durability-of-response-in-new-and-recurrent-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer-at-aua-2024 2024-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/150f90389bd8a35b/fresenius-kabi-launches-first-actemra-r-biosimilar-in-u-s-market-as-biosimilar-landscape-expands 2024-05-03T16:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/cf62dce0c2906d42/nhs-approves-oxbryta-for-sickle-cell-disease-following-price-reduction-agreement 2024-05-03T01:38:05+00:00 weekly 0.7 https://trial.medpath.com/news/cb6f822b6853c9e1/gh-research-reports-first-quarter-2024-financial-results-and-business-updates 2024-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0edf6a21c0d1c1db/fdas-accelerated-approval-of-sarepta-dmd-gene-therapy-comes-under-fire-biospace 2024-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6fcc36d64ccef679/lifileucel-first-cellular-therapy-approved-for-cancer 2024-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4358f30b012b72c9/ich-e6-r3-guidelines-set-to-transform-clinical-trial-quality-management-in-2025 2024-05-02T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f3b1b0643c179f4f/immutep-s-triple-combination-therapy-shows-promising-results-in-soft-tissue-sarcoma-phase-ii-trial 2024-05-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5739231d724ba4c6/atsena-therapeutics-reports-promising-results-for-xlrs-gene-therapy-using-novel-spreading-capsid 2024-05-01T14:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/dfd9d96a77878c97/fda-issues-new-draft-guidance-on-allogeneic-cell-based-medical-products 2024-05-01T13:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/11eef8ba56a42edc/mindbio-explores-dual-listing-on-senior-exchange-following-successful-clinical-trials 2024-05-01T09:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/2d111edb2bc602fa/newron-s-evenamide-shows-breakthrough-results-in-treatment-resistant-schizophrenia-phase-ii-iii-trials 2024-05-01T02:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/0681d5ba3639bcf8/chime-biologics-and-mabgeek-achieve-mg-k10-ppq 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4be74ad413bfca9b/jacobio-pharma-announced-its-kras-g12c-inhibitor-reached-the-primary 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d04513051f8f64f5/university-of-florida-mrna-vaccine-shows-rapid-immune-response-against-glioblastoma-in-first-human-trial 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2cace1f6b03fab9f/gsk-makes-a-strong-start-to-2024-with-improving-outlook-for-the-year 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/43f546d6dff9747f/seastar-medical-secures-3-6-million-nih-grant-for-heart-failure-device-study 2024-04-30T12:36:06+00:00 weekly 0.7 https://trial.medpath.com/news/04b2bd84233a1c6c/eton-pharmaceuticals-announces-submission-to-fda-of-new-drug-application-for-et-400-hydrocortisone-oral-solution 2024-04-30T02:04:44+00:00 weekly 0.7 https://trial.medpath.com/news/59a56665542b9b49/the-u-s-food-drug-administration-fda-approves-updated-lupkynis-r-voclosporin-label-to-include-long-term-data-from-the-aurora-clinical-program 2024-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/79597a026cd4231d/fda-implements-historic-regulation-of-laboratory-developed-tests-with-new-final-rule 2024-04-29T09:41:59+00:00 weekly 0.7 https://trial.medpath.com/news/124b464d2d6d8254/iterum-therapeutics-resubmits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem 2024-04-29T02:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/053b188f9923ef79/ftc-intensifies-scrutiny-of-orange-book-patent-listings-in-pharmaceutical-industry 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d60cc6703971974d/fda-approves-boston-biotechs-drug-for-ultra-rare-disease-of-immune-system-the-boston-globe 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4f2e2ac3eb3b0c17/accord-biopharma-inc-announces-u-s-food-drug-administration-approval-of-hercessitm-trastuzumab-strf-a-biosimilar-to-herceptin-r-trastuzumab-for-the-treatment-of-several-forms-of-her2-overexpressing-cancer 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7df047d7a2e0cbb1/immix-biopharma-awarded-european-union-orphan-drug-designation-for-nxc-201-in-multiple-myeloma-marketscreener 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3d77a8a70f39637d/pfizer-launches-beqvez-gene-therapy-for-hemophilia-b-with-novel-warranty-program-at-3-5m 2024-04-28T22:50:03+00:00 weekly 0.7 https://trial.medpath.com/news/03680e72660b4b19/india-s-cdsco-rejects-pfizer-s-clinical-trial-waiver-for-multiple-myeloma-drug-elranatamab 2024-04-27T18:36:58+00:00 weekly 0.7 https://trial.medpath.com/news/6d9c677951b3796e/fda-approves-pfizer-s-3-5-million-gene-therapy-beqvez-for-hemophilia-b-treatment 2024-04-26T11:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/a4161ac391bd1f2f/fda-approves-biktarvy-label-update-with-data-for-pregnant-adults-with-hiv 2024-04-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/74ef3bf53cbf61d9/duchenne-muscular-dystrophy-gene-therapy-trial-shows 2024-04-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3a853c8ca2eaa727/first-personalized-mrna-vaccine-for-melanoma-enters-uk-clinical-trials 2024-04-25T23:45:21+00:00 weekly 0.7 https://trial.medpath.com/news/d692109daf10a32f/tease-3-study-reports-positive-interim-data-for-stargardt-disease-treatment 2024-04-25T16:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/52296fe8d3f26d9f/starton-therapeutics-completes-enrollment-for-star-lld-phase-1b-trial-in-multiple-myeloma-reports-superior-safety-profile 2024-04-25T12:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/38d223893b7a28c5/xaira-therapeutics-launches-with-record-1-billion-funding-to-revolutionize-ai-driven-drug-discovery 2024-04-25T00:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/aaa0ab6561c548dd/car-nk-cell-therapy-shows-promise-as-safer-alternative-to-car-t-with-comparable-efficacy-in-early-clinical-trials 2024-04-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b2acd16f90d5ae83/advancing-cancer-treatment-the-promise-of-oncolytic-virotherapy-combinations 2024-04-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d052a74ee6c9a63d/mirvetuximab-soravtansine-gynx-approved-for-ovarian-cancer 2024-04-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3e16fea2f5992072/immutep-announces-positive-preliminary-topline-results-from-tacti-003-cohort-b 2024-04-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f8de809af800ca4c/fda-s-new-approval-for-wegovy-opens-medicare-coverage-for-millions-with-obesity 2024-04-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4c9d61d5bb44e675/fda-approves-immunitybio-s-anktiva-for-bladder-cancer-marking-major-milestone-for-soon-shiong-s-immunotherapy-approach 2024-04-23T20:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/c5ba90c9fc918e1d/tirzepatide-shows-promise-as-first-pharmaceutical-treatment-for-obstructive-sleep-apnea-in-obesity 2024-04-23T17:13:02+00:00 weekly 0.7 https://trial.medpath.com/news/9f4d60c8c1ee4380/tislelizumab-approved-in-europe-for-non-small-cell-lung-cancer-treatment 2024-04-23T16:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/56ffc5e63a924221/actinogen-xanamia-acw0009-phase-2b-trial-for-mci-and-mild-alzheimer-s-disease 2024-04-23T03:38:04+00:00 weekly 0.7 https://trial.medpath.com/news/4a92e8e3cf7a4828/press-release-rilzabrutinib-luna-3-phase-3-study-met 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ad70830317cea2a8/hanmi-pharmaceutical-partners-with-msd-to-test-novel-bispecific-antibody-bh3120-in-combination-with-keytruda 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f8452ec956ae008c/fda-approves-alvotech-teva-s-ustekinumab-biosimilar-for-psoriasis-and-psoriatic-arthritis 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3863b6982105c5b8/fda-approves-immunitybio-s-bladder-cancer-treatment-los-angeles-times 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/27f6228e621c192d/eu-approves-pfizer-s-emblaveo-first-in-class-antibiotic-for-multi-drug-resistant-infections 2024-04-22T23:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/0d0a1c5e81a7a750/acadia-s-rett-syndrome-drug-under-priority-review-in-canada 2024-04-22T13:15:22+00:00 weekly 0.7 https://trial.medpath.com/news/cd5caf2bae8d58e2/abeona-therapeutics-provides-regulatory-update-on-pz-cel 2024-04-22T04:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/1e2d3a4c6e889546/fate-therapeutics-treats-first-lupus-patient-with-off-the-shelf-car-t-cell-therapy-ft819 2024-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b4875acf834245dd/a-cheap-drug-may-slow-down-aging-a-study-will-determine-if-it-works-npr 2024-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9133d7e789d35fc2/cilta-cel-allows-for-treatment-free-period-in-early-r-r-multiple 2024-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cdb19d0e906f60ac/fda-clears-ind-for-arbor-biotechnologies-abo-101-gene-editing 2024-04-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e4326ee5a4320587/ai-tool-predicts-responses-to-cancer-therapy-using-single-cell-omics 2024-04-18T19:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/6fd5ddaedabcc10b/adjuvant-pembrolizumab-shows-improved-overall-survival-in-keynote-564-trial-for-ccrcc 2024-04-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/76c5a7e87023761d/nexcella-an-immix-biopharma-subsidiary-on-track-to-dose-nxc-201-patients-in-united-states-biospace 2024-04-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dd637ba029ec1cc2/scandion-oncology-announces-rights-issue-to-raise-approximately-sek-60-million 2024-04-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f10ca6801e0e9a1e/psyence-biomed-announces-phase-iib-clinical-trial-listing-on-the-australian-new-zealand-clinical-trials-registry-anzctr 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c8c8f0f4f8154ecb/diamyd-medical-ab-new-publication-highlights-safety-and 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/db36fcad1fe149e1/fda-approves-ryzumvi-for-treating-drug-induced-mydriasis 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/89ea6881f735981d/evaxion-announces-phase-2-clinical-trial-update-first-patient-completes-dosing-with-personalized-cancer-vaccine-evx-01 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ed1280e409da3d2f/xeltis-announces-latest-results-from-axess-trials-to-be-presented-at 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fd66061180c3e5dd/boehringer-ingelheim-sets-sights-on-launching-25-new-treatments-by-2030 2024-04-16T15:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/43d4f8b38a80860a/two-major-breakthroughs-in-fragile-x-syndrome-treatments 2024-04-16T13:33:24+00:00 weekly 0.7 https://trial.medpath.com/news/18c2a5d5db2d2a7f/askbio-presents-positive-18-month-phase-ib-trial-results-for-ab-1005-gene-therapy-in-parkinsons-disease 2024-04-16T12:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/8ce23804ba39a484/immunotherapy-advances-in-endometrial-cancer-focus-shifts-to-pmmr-disease-following-success-in-dmmr-population 2024-04-16T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1f6d34fb73781cd1/volastra-therapeutics-initiates-phase-ib-trial-of-sovilnesib-for-platinum-resistant-ovarian-cancer 2024-04-16T11:00:25+00:00 weekly 0.7 https://trial.medpath.com/news/a10e1d02d5d87dec/cancervax-announces-promising-new-drug-to-treat-a-deadly-children-s-cancer 2024-04-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f66b7dfe9dd9fa0a/spatial-comparison-of-molecular-features-associated-with 2024-04-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b024d8e635cf3636/innate-pharma-announces-advancement-of-sanofi-developed-nk-cell-engager-sar443579-iph6101-to-phase-2-for-blood-cancer-patients 2024-04-15T13:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/7e19f7606d0f2386/11-clinical-trials-that-have-researchers-excited-in-2024 2024-04-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a53ae3834d1dfadc/norgine-b-v-submits-marketing-authorisation-application-via-project 2024-04-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/49da965f184003d4/pharma-stock-roundup-azn-voydeya-gets-fda-nod-mrk-kras-inhibitor-enters-phase 2024-04-12T22:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/1d754667c1651084/why-is-viatris-vtrs-down-3-5-since-last-earnings-report 2024-04-12T13:08:59+00:00 weekly 0.7 https://trial.medpath.com/news/e262fa778fb8115d/aldeyra-aldx-stock-rallies-43-in-one-week-here-s-why 2024-04-12T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/1b8e6914dc049617/pfizer-rsv-shot-meets-goals-in-trial-of-high-risk-adults-under-age-60 2024-04-12T12:49:50+00:00 weekly 0.7 https://trial.medpath.com/news/56b6d9d0a529c9ba/vertex-vrtx-begins-rolling-nda-filing-for-acute-pain-drug 2024-04-12T12:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/1870407d626f08b2/fda-s-odac-recognizes-mrd-as-an-accepted-end-point 2024-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4785c34bd87e47a7/can-amivantamab-and-lazertinib-replace-osimertinib-in 2024-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b54bd8f18ddd4af0/roche-receives-fda-breakthrough-device-designation-for-ptau217-blood-test-to-aid-in-early-alzheimers-diagnosis 2024-04-11T14:48:00+00:00 weekly 0.7 https://trial.medpath.com/news/db011e406616553c/vigeneron-doses-first-patient-in-phase-1b-clinical-trial-of-vg901-for-retinitis-pigmentosa-treatment 2024-04-11T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dbe53e13e28bc095/european-parliament-approves-major-pharmaceutical-reform-package-with-modified-exclusivity-terms 2024-04-11T00:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/eacc3efaf6644541/alzheimers-trial-brings-at-risk-patients-hope-for-the-future-but-new-doubts-in-the-present-the-globe-and-mail 2024-04-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/841ebb0cd8f9c0d6/torl-biotherapeutics-announces-158-million-oversubscribed-series-b-2-financing-to-advance-the-clinical-development-of-its-novel-antibody-drug-conjugate-adc-oncology-pipeline 2024-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/83f3303c759915fe/a-new-hope-for-men-with-metastatic-prostate-cancer 2024-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e239ba007a66127f/spectral-medical-provides-tigris-trial-update-the-globe-and-mail 2024-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1c2ba678fa7b0025/aacr-2024-linvoseltamab-demonstrates-promising-results-in-heavily-pre-treated-multiple-myeloma-patients 2024-04-09T16:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/7c833d17ceb0f3c4/wegovy-can-help-reduce-heart-failure-symptoms-even-when-people-don-t-lose-as-much-weight 2024-04-09T15:29:14+00:00 weekly 0.7 https://trial.medpath.com/news/b061993b08bcff7f/genomics-market-set-to-reach-157-47-billion-by-2033-driven-by-personalized-medicine-and-government-funding 2024-04-09T05:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/2d7e530dd46a96d2/combination-immunotherapy-strategies-show-promise-in-overcoming-nsclc-treatment-resistance 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8a59ce72cfe1b49b/car-t-cell-therapy-could-reach-beyond-cancer-medicine-net 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4c82b1b4c65ada56/enhanced-efficacy-of-tace-combined-with-tkis-and-icis-in-treating-hcc 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/46448898036ebeea/artificial-intelligence-analysis-of-dna-fragmentomes-and-protein-biomarkers-noninvasively-detects-ovarian-cancer-news-releases-aacr 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b38269b7904f8ab1/corcept-cort-completes-enrollment-in-ovarian-cancer-study 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e831596f01a66448/fda-grants-breakthrough-therapy-designation-to 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3b3eb9c3ba83de54/augustine-therapeutics-raises-eur78-million-series-a-to-advance-novel-hdac6-inhibitor-for-charcot-marie-tooth-disease 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9ffe90eb2ea1f3d0/phanes-therapeutics-pt217-granted-fast-track-designation-by-the-fda 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/56051852500ef4c1/supernus-provides-regulatory-update-for-spn-830 2024-04-08T22:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/39d3518ce183fd03/oric-pharmaceuticals-unveils-promising-cancer-drug-data-at-aacr-meeting 2024-04-08T14:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/5311b35aefb5151c/cancer-immunotherapy-market-set-to-reach-usd-296-billion-by-2033-growing-at-8-9-cagr 2024-04-08T11:23:10+00:00 weekly 0.7 https://trial.medpath.com/news/bb8282b50ea90df8/stealth-biotherapeutics-announces-fda-acceptance-of-new-drug-application-for-elamipretide-for-the-treatment-of-barth-syndrome 2024-04-08T04:04:03+00:00 weekly 0.7 https://trial.medpath.com/news/1b35fcb70dde7d81/uc-davis-health-pioneers-novel-heart-valve-repair-with-newly-approved-device 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/425b6cf173f4b212/shorla-oncology-announces-fda-filing-acceptance-of-new-drug 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b4f5be8b13cf03c4/fda-accepts-shorlas-oral-liquid-leukaemia-drug-nda-pharmaceutical-technology 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9b7f0e92d479f550/next-generation-parp-inhibitor-shows-promise-in-treating-hrr-deficient-breast-cancer 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bd4efa2bed7a4b78/ocugen-s-ocu400-becomes-first-gene-therapy-to-enter-phase-3-for-broad-retinitis-pigmentosa-treatment 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/026fecc3701f4f30/study-reveals-most-cancer-drugs-with-accelerated-fda-approval-fail-to-demonstrate-clinical-benefit-after-five-years 2024-04-07T18:06:10+00:00 weekly 0.7 https://trial.medpath.com/news/fc61ef375bcfe40b/single-injection-of-zilebesiran-reduces-blood-pressure-by-up-to-12-mmhg-in-phase-2-trial 2024-04-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ce74c7cdb0f9a0f8/investigational-mrna-vaccine-shows-promise-in-fighting-pancreatic-cancer 2024-04-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/faae153e817a7109/igc-pharma-expands-calma-phase-2-trial-for-alzheimer-s-agitation-treatment-with-new-oklahoma-site 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2fc7b4908559a192/fda-accepts-ptc-therapeutics-nda-for-sepiapterin-to-treat-pku 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a8ae3bfc3809edca/meta-analysis-confirms-superior-efficacy-of-perioperative-immunotherapy-plus-chemotherapy-in-resectable-nsclc 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7b3d63a079bc73ab/axsome-therapeutics-announces-successful-completion-of-phase-3-clinical-trial-for-alzheimers-disease-agitation 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0472ee9bc559f08e/signatera-mrd-test-shows-exceptional-survival-outcomes-in-muscle-invasive-bladder-cancer-surveillance 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f3dbe8a568caec34/cytokinetics-aficamten-shows-superior-cardiac-benefits-over-standard-treatment-in-hypertrophic-cardiomyopathy 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8bb2c7ce77ffa611/odronextamab-demonstrates-high-efficacy-in-lymphoma-treatments-at-ash-meeting 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/18e6c2f611245097/carvykti-r-is-the-first-and-only-bcma-targeted 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/996571c5125e8333/aspire-biopharma-s-sublingual-aspirin-shows-twice-faster-action-in-heart-attack-treatment-trial 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fe05b95c30bda390/stoke-therapeutics-and-biogen-initiate-phase-3-emperor-trial-for-zorevunersen-in-dravet-syndrome 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ed3a5978eea5d6c9/clene-advances-cnm-au8-toward-potential-als-approval-with-fda-meetings-and-biomarker-analysis 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f4a87e8f4804565b/fda-grants-priority-review-for-verastem-oncology-s-new-drug-application-for-recurrent-kras-mutant-lgsoc-treatment 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b6fe256d50b2d81e/microbot-medical-secures-key-patent-for-modular-robotic-system-expanding-market-potential-to-6-million-procedures 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f248bfbe38276d72/fda-approves-expanded-use-of-trikafta-for-cystic-fibrosis-treatment 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b28a1cc868ed7265/stoke-therapeutics-announces-alignment-with-global-regulatory-agencies 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f7cf60397bb3e322/merck-launches-phase-3-trial-of-mk-1084-plus-pembrolizumab-for-kras-g12c-mutated-nsclc 2024-04-04T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/2dfc317ed246b52c/ai-driven-real-world-evidence-revolution-new-paradigm-for-biotech-companies 2024-04-04T06:44:19+00:00 weekly 0.7 https://trial.medpath.com/news/ba7dee84330e4f36/tpvr-with-self-expanding-harmony-valve-associated-with 2024-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/040ffc269ddc978b/caribou-biosciences-expands-clinical-development-of-cb-010-with-fda-clearance-of-ind-in-lupus 2024-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bb4b151fa6a51e30/india-launches-world-s-most-affordable-car-t-cell-therapy-at-one-tenth-international-cost 2024-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/919d43acd7fd9303/fda-requires-fast-track-designation-for-subcutaneous-formulation-of-leqembi-for-alzheimer-s-disease 2024-04-03T21:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/e75bdc07cf915ad8/court-rules-in-favor-of-arbutus-in-patent-dispute-over-moderna-s-covid-19-vaccine-delivery-technology 2024-04-03T19:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/f6f2d4bd391ad856/ind-application-submitted-to-fda-for-synkir-310-trial-in-relapsed-refractory-b-nhl 2024-04-03T16:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/326d140e00ddaf6a/key-strategic-decisions-shaping-the-future-of-cell-and-gene-therapy-development 2024-04-03T04:20:40+00:00 weekly 0.7 https://trial.medpath.com/news/505521ddab95ce4f/behavioral-science-emerges-as-key-strategy-for-driving-adoption-of-novel-therapies-in-biopharma 2024-04-03T01:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/ead8a8914ba53f5c/study-of-adjuvant-cemiplimab-versus-placebo-after-surgery-for-high-risk-cutaneous-squamous-cell-carcinoma 2024-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a43e08cc8d13b76f/sanofi-hits-reset-on-drug-from-2-5b-deal-after-lower-than-projected-efficacy-in-trials 2024-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/241e9cd921f29e01/sandoz-receives-fda-approval-for-first-denosumab-biosimilars-in-us-and-canada 2024-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7ce25aefd04c8319/jazz-pharmaceuticals-completes-zanidatamab-biologics-license-application-for-previously-treated-her2-positive-metastatic-biliary-tract-cancer 2024-04-02T18:04:38+00:00 weekly 0.7 https://trial.medpath.com/news/f621e6e218d46fcb/study-highlights-preference-for-bladder-sparing-treatments-in-high-risk-nmibc-patients 2024-04-02T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d72bfa0b715d2c69/datopotamab-deruxtecan-biologics-license-application-accepted-in-the-us-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer 2024-04-02T01:04:35+00:00 weekly 0.7 https://trial.medpath.com/news/87a7ce2ea5ffbc60/eflornithine-for-neuroblastoma-ema-approval-timelines-and-how-to-avoid 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/033afd9599b52597/agios-strategy-shift-pays-off-with-fda-approval-of-first-drug-for-rare 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd8cb4bbea4f77da/direct-and-selective-pharmacological-disruption-of-the-yap 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/06e3d23b9687f134/fda-approves-pharmaessentia-interferon-drug-for-a-rare-type-of-blood 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0318e4bd6c5a8dfe/cretostimogene-monotherapy-demonstrated-75-2-complete-response-rate-in 2024-04-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f322ad98cac0eac9/sanofi-denali-neuro-drug-fails-mid-stage-trial-in-als-ms-study-is 2024-04-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/afbcae6ecde7732d/evaluating-mfars-in-pediatric-friedreich-s-ataxia-insights-from-the-fachild-study 2024-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9462d11682aab001/fda-clears-sequel-s-twiist-aid-system-first-insulin-pump-to-directly-measure-every-micro-dose 2024-03-30T19:00:24+00:00 weekly 0.7 https://trial.medpath.com/news/04dc2eacea78034a/fda-flexes-its-new-accelerated-approval-authorities-hoping-to 2024-03-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/07824f8bfe32e2b0/milestone-pharmaceuticals-announces-resubmission-of-new-drug-application-for-etripamil-for-treatment-in-paroxysmal-supraventricular-tachycardia 2024-03-28T19:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/fe071d48492b5307/aldeyra-therapeutics-announces-clinical-development-plan-for-resubmission-of-new-drug-application-for-reproxalap-in-dry-eye-disease 2024-03-28T19:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/66bc4dc893b332e6/china-s-national-medical-products-administration-accepts 2024-03-28T14:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/75e5e3062760715e/nivolumab-shows-consistent-benefit-in-resectable-nsclc-regardless-of-neoadjuvant-treatment-duration 2024-03-28T14:05:51+00:00 weekly 0.7 https://trial.medpath.com/news/7a4eb13162627287/vicore-s-buloxibutid-shows-promising-lung-function-improvement-in-phase-2a-ipf-trial 2024-03-28T10:08:25+00:00 weekly 0.7 https://trial.medpath.com/news/ac25ff5a0b1cf4c9/applied-therapeutics-provides-fda-update-on-pdufa-target-action-date-for-govorestat-for-the-treatment-of-classic-galactosemia 2024-03-28T00:03:07+00:00 weekly 0.7 https://trial.medpath.com/news/37f8fa8127716ddc/u-k-becomes-the-first-country-to-release-detailed-data-on-sponsors-that-fail-to-register-clinical-trials 2024-03-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2766aa6ea8658336/sequana-medical-announces-2023-full-year-results-and-2024-outlook 2024-03-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f1ed27512a24886d/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-joint-ventures-from-2016-2024 2024-03-27T20:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/3ad7c9f034736f39/altimmune-s-obesity-drug-shows-promising-results-in-reducing-fat-with-minimal-muscle-loss 2024-03-27T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0656e467d3826427/fda-warns-against-high-concentration-lidocaine-products-in-cosmetic-procedures 2024-03-27T10:58:50+00:00 weekly 0.7 https://trial.medpath.com/news/291ab3c95a5548cf/stoke-therapeutics-stok-up-on-upbeat-dravet-syndrome-study-data 2024-03-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0fb9a07501b43eed/syndax-announces-fda-priority-review-of-nda-for-revumenib-for-the-treatment-of-relapsed-refractory-kmt2ar-acute-leukemia 2024-03-26T02:03:21+00:00 weekly 0.7 https://trial.medpath.com/news/686912f3add03450/intrabio-announces-u-s-fda-accepts-new-drug-application-for-ib1001-for-the-treatment-of-niemann-pick-disease-type-c 2024-03-26T02:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/b194be0e661c606d/avecho-launches-largest-phase-iii-trial-of-cbd-for-insomnia-in-australia 2024-03-26T00:57:22+00:00 weekly 0.7 https://trial.medpath.com/news/c8fb01f947836c42/chugai-s-vabysmo-receives-japanese-approval-for-retinal-vein-occlusion-treatment 2024-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8f104f1e4f558bbc/phase-ii-study-shows-belumosudil-s-efficacy-in-treating-chronic-graft-versus-host-disease 2024-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/952f6fe83ca4d74b/pancreatic-cancer-survivor-funds-clinical-trial-to-aid-future-patients 2024-03-25T17:48:32+00:00 weekly 0.7 https://trial.medpath.com/news/e3f1da1e7808a8e0/lipocine-completes-dosing-in-pivotal-study-for-oral-postpartum-depression-treatment-lpcn-1154 2024-03-25T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a086b9b8169aa928/fda-issues-complete-response-letters-for-regeneron-s-odronextamab-in-non-hodgkin-lymphoma 2024-03-25T07:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/75be2a65dd534d47/chemomab-secures-global-patent-protection-for-cm-101-antibody-targeting-primary-sclerosing-cholangitis 2024-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7c4c57c2283342dc/pharmaceutical-industry-leadership-shuffle-major-executive-appointments-signal-strategic-shifts-across-biotech-and-pharma 2024-03-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4f215ee78677b72d/a-review-of-the-clinical-efficacy-of-fda-approved-antibody 2024-03-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c7e348e723dc775d/pan-foundation-study-reveals-c-grade-for-u-s-healthcare-access-highlighting-systemic-disparities 2024-03-22T09:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/c144aa645bf6532a/biophytis-advances-ruvembri-to-phase-3-trial-for-sarcopenia-treatment-following-promising-phase-2-results 2024-03-22T07:01:04+00:00 weekly 0.7 https://trial.medpath.com/news/c6ea88ea9b00324d/dermata-therapeutics-advances-phase-3-trial-for-novel-once-weekly-acne-treatment-dmt310 2024-03-21T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/5cfdb8d0ec134f94/european-patent-office-upholds-umeclidinium-vilanterol-combination-patent-despite-opposition-challenges 2024-03-21T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6b8bceb41531f93c/ai-revolutionizes-drug-discovery-industry-leaders-share-latest-advances-at-london-conference 2024-03-21T07:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/ec6510a0e35014d5/clinical-trials-support-services-market-set-to-reach-47-1-billion-by-2032-amid-growing-outsourcing-trend 2024-03-21T05:53:14+00:00 weekly 0.7 https://trial.medpath.com/news/3e3ca0641b550bc2/elixir-medical-receives-fda-breakthrough-device-designation-for-the-dynamx-btk-system-for-use-in-the-treatment-of-chronic-limb-threatening-ischemia-resulting-from-below-the-knee-arterial-disease 2024-03-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4b8ab397fc3fd19d/scandion-oncology-reports-promising-updated-phase-ii-corist-data 2024-03-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f6d74d6db0e89fc8/corvus-pharmaceuticals-updates-on-clinical-trials-and-financials-for-2023 2024-03-20T12:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/52df9cf761818802/lenvatinib-pembrolizumab-combo-misses-survival-endpoints-in-endometrial-cancer-trial 2024-03-20T11:54:57+00:00 weekly 0.7 https://trial.medpath.com/news/fa81b9bfe8eb0e98/acelyrin-reports-promising-early-stage-data-for-thyroid-eye-disease-treatment 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/905cab61b2f2ca33/acelyrin-announces-positive-phase-1-2-poc-data-for-first-subcutaneous-anti-igf-1r-to-demonstrate-clinical-responses-in-thyroid-eye-disease 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/17cdecfc2c4330a3/stat-readout-orchard-acelyrin-novo-astrazeneca 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ce8c3b705a599ac4/fda-accepts-new-drug-application-for-dfd-29-for-rosacea-treatment 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/76bd7a07b5305024/global-study-on-friedreich-s-ataxia-aims-to-enhance-understanding-and-treatment 2024-03-19T19:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/50494564b35b93f4/novo-nordisk-s-amycretin-pill-shows-promising-13-weight-loss-in-early-trial 2024-03-19T15:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/fc2691c1ab2f88fd/ptc-therapeutics-announces-plans-to-resubmit 2024-03-19T14:27:37+00:00 weekly 0.7 https://trial.medpath.com/news/4241934732bbc127/bayer-prepares-to-seek-approval-for-menopause-drug-elinzanetant-following-positive-phase-3-trial-results 2024-03-19T11:58:00+00:00 weekly 0.7 https://trial.medpath.com/news/f56ecd476b6a6a49/nvidia-expands-ai-healthcare-footprint-with-major-drug-discovery-partnerships 2024-03-19T07:01:17+00:00 weekly 0.7 https://trial.medpath.com/news/f3b5dee7f7959727/petros-pharmaceuticals-successfully-launches-ai-tool-in 2024-03-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/47fd9b9223b49446/novel-non-opioid-pain-medications-hold-promise-but-face-challenges 2024-03-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/15458b7c3f093400/ocuterra-s-phase-ii-diabetic-retinopathy-trial-fails-to-meet-endpoints 2024-03-15T09:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/954d650a8f42b828/experts-call-for-early-referral-system-to-expand-car-t-cell-access-in-large-b-cell-lymphoma 2024-03-15T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/50210d3a50dc850a/heparegenix-publishes-data-for-its-first-in-class-mkk4 2024-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/92dc4c71a123b078/expired-rfa-da-25-052-tools-for-decentralized-clinical-trials 2024-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/63530da34cf99d87/madrigal-pharmaceuticals-announces-fda-approval-of-rezdiffratm-resmetirom-for-the-treatment-of-patients-with-noncirrhotic-nonalcoholic-steatohepatitis-nash-with-moderate-to-advanced-liver-fibrosis 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9ad5e472412205e2/gilgamesh-pharmaceuticals-awarded-14-million-national-institute-on-drug-abuse-grant-to-advance-novel-cardiac-safe-ibogaine-analog-for-the-treatment-of-opioid-use-disorder 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/99457c87a0872e1e/protein-discovery-offers-new-hope-for-treating-aggressive-cancer 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/70ad90f404eaee2e/korean-drugmakers-lead-in-biosimilar-market-and-new-denosumab-eculizumab-deals 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fccb950c52e764ce/mda-2024-dmd-cell-therapy-cap-1002-continues-to-preserve-limb 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a3c94ecda4692d74/i-mab-reports-full-year-2023-financial-results-and 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bce450a712828363/phase-3-drug-trial-for-rare-chronic-kidney-disease-achieves-key 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/93fc9abbd188ac70/lyt-200-receives-fda-orphan-drug-designation-for-acute-myeloid-leukemia-treatment 2024-03-13T18:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/f226ec12cee3d1f3/the-zacks-analyst-blog-highlights-moderna-rapt-therapeutics-iovance-sarepta 2024-03-13T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/00f1828bfcf889e0/crispr-clinical-trials-a-2024-update 2024-03-13T17:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/ded8f6340cab27d4/q4-2023-clearside-biomedical-inc-earnings-call 2024-03-13T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/6be64d7da6ad4f8e/tyra-biosciences-inc-tyra-reports-increased-r-d-investments-amid-pipeline 2024-03-13T13:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/1ac2d1d32c724938/pmv-pharmaceuticals-inc-pmvp-reports-full-year-2023-financial-results 2024-03-13T13:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/e0c7003b7e12bc25/biontech-se-bntx-q4-2023-earnings-call-transcript 2024-03-13T11:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/1190171f6a88420d/q4-2023-vaxart-inc-earnings-call 2024-03-13T11:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/b04c66da82f9190b/digital-evolution-in-clinical-trials-epros-show-97-compliance-rate-in-latest-study 2024-03-13T09:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/ffb53d5b7961ebbf/preliminary-clinical-trial-results-show-dramatic-regression-of-glioblastoma-after-next-generation-car-t-therapy 2024-03-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2f22c5346c8482ba/fractyl-health-announces-promising-preclinical-findings-for-glp-1-gene-therapy-in-diabetes-and-obesity 2024-03-12T11:46:03+00:00 weekly 0.7 https://trial.medpath.com/news/0c43e99d8c1974b7/biovica-signs-master-service-agreement-to-support-next-generation-cdk4-6-inhibitor-development-for-breast-cancer 2024-03-12T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a17f65fa9954ba74/vir-biotechnology-receives-fda-breakthrough-therapy 2024-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ccf2237da8e4e98e/nih-launches-comprehensive-clinical-trials-to-address-debilitating-long-covid-symptoms 2024-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8586ff29355dd055/phase-ii-trial-combines-cisplatin-pembrolizumab-and-radiation-therapy-for-advanced-vulvar-squamous-cell-carcinoma 2024-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9990cd5f98e2fc06/can-b-corp-acquires-cannabis-patents-valued-at-122-million-through-court-assignment 2024-03-11T12:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/f2ff324d23b815b0/nusano-opens-radiochemistry-laboratory-to-advance-medical-radioisotope-production-for-cancer-therapy 2024-03-11T03:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/f3de9588117e2e83/enfortumab-vedotin-and-pembrolizumab-show-significant-survival-benefit-in-urothelial-cancer-treatment 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7f28de9730ade7f2/gilead-and-merck-report-promising-phase-2-results-for-once-weekly-hiv-combination-therapy 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/858b46554c5a7ed7/acelyrin-inc-announces-long-term-32-week-data-from-the-phase-2b-trial-of-izokibep-in-hidradenitis-suppurativa-demonstrating-sustained-responses-and-deepening-clinical-benefit-improving-quality-of-life-for-patients-march-11-2024-at-08-02-am-edt-marketscreener 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bebfc808269d4d98/acelyrin-inc-announces-positive-top-line-results-from-its-globenewswire 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/089deec4f169f212/denver-lab-developing-first-of-its-kind-tool-for-early-ovarian-cancer-detection-cbs-colorado 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1d3784236d7a219a/recursion-obtains-fda-approval-for-ai-discovered-cancer 2024-03-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4c84e25835e54450/benefit-of-belantamab-mafodotin-based-regimen-supported-in-multiple 2024-03-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/52b881882c442cf4/subcutaneous-nivolumab-offers-a-promising-alternative-for-kidney-cancer-treatment 2024-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ad36cc664d65df24/promontory-therapeutics-completes-enrollment-in-phase-2-trial-of-pt-112-for-late-stage-metastatic-prostate-cancer 2024-03-08T08:02:25+00:00 weekly 0.7 https://trial.medpath.com/news/62e448452873a7a9/fda-to-convene-advisory-committee-for-eli-lilly-s-alzheimer-s-drug-donanemab 2024-03-08T07:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/33ffed583bbcca5c/sexually-transmitted-infections-in-san-francisco-have 2024-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3c8ddf090f65d9a5/als-drug-fails-large-clinical-trial-and-may-be-withdrawn-from-market-cnn 2024-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8f00500e1890830a/immuron-announces-positive-results-for-travelan-r-progressing-to-phase-3-clinical-trials-in-the-us 2024-03-07T11:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/b41a1f54323ee12b/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder 2024-03-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c864a0291e3b689b/neoadjuvant-adjuvant-vs-neoadjuvant-only-pd-1-and-pd-l1-inhibitors-for 2024-03-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7045f63be3991c17/cabozantinib-plus-nivolumab-emerges-as-preferred-first-line-treatment-for-advanced-renal-cell-carcinoma 2024-03-06T22:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/fee142d48cf95018/fda-grants-breakthrough-device-designation-for-phospho-tau-217-blood-test-for-alzheimer-s-disease 2024-03-06T19:08:12+00:00 weekly 0.7 https://trial.medpath.com/news/0046538023671d10/bluerock-therapeutics-reports-positive-18-month-data-in-phase-i-trial-for-parkinson-s-disease-treatment 2024-03-06T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/fdd46813bc91952d/akeso-initiates-phase-iii-trial-of-cadonilimab-bispecific-antibody-for-pd-l1-negative-nsclc 2024-03-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5c9f02f098b9d4a4/advancements-in-cgb-500-for-atopic-dermatitis-treatment 2024-03-05T16:00:28+00:00 weekly 0.7 https://trial.medpath.com/news/48818e6e318b5e7e/real-world-teclistamab-data-shows-comparable-efficacy-to-clinical-trials-despite-higher-toxicity-rates-in-multiple-myeloma 2024-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/77c3e9c0d63975ef/camurus-announces-fda-acceptance-of-nda-submission-for-oclaiztm-for 2024-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8475c98c48dfdbd4/maia-biotechnology-ceo-details-immuno-oncology-cancer-treatment 2024-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fc79d93eb3d656b7/transformative-trends-reshape-pharmaceutical-r-d-landscape-in-2024-ai-crispr-and-rare-disease-innovation-take-center-stage 2024-03-04T08:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/61f4a75aa29d8131/rop-et-a-prospective-phase-iii-trial-investigating-the 2024-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8bcef24cf28942d4/new-clinical-trial-design-in-precision-medicine 2024-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/904f22c1b4b4e4df/ucsf-trigeminal-neuralgia-clinical-trials-for-2024-san-francisco 2024-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/be0df7b10449ad7f/global-phase-3-trial-tests-efzofitimod-as-steroid-sparing-treatment-for-sarcoidosis 2024-03-01T07:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/d26562c57c6ddff4/eu-clinical-trials-directive-transition-deadline-looms-companies-must-act-by-january-2025 2024-03-01T01:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/5376b17e4c855e7f/jacobio-pharma-receives-ind-approval-for-p53-y220c-activator-jab-30355-in-the-us 2024-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ce283adc61034fb8/4sc-files-marketing-authorisation-application-with-ema-for-resminostat 2024-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dca06c50502a5592/niaid-halts-clemastine-arm-of-ms-trial-after-fivefold-increase-in-disease-progression 2024-02-29T18:36:32+00:00 weekly 0.7 https://trial.medpath.com/news/3d98b9ef15517a11/new-research-reveals-significant-disparities-in-psoriasis-impact-across-racial-and-ethnic-groups 2024-02-29T11:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/a021346b7002d0dd/cu-cancer-center-researchers-advance-novel-cancer-therapy-with-svc112-molecule 2024-02-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0672b2525d498a4c/fire1-completes-enrollment-in-u-s-early-feasibility-study-of 2024-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cdf724ecaae0eda5/fda-grants-accelerated-approval-to-lifileucel-for-unresectable-or-metastatic-melanoma 2024-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b9efbd6e589f5c5b/til-therapy-offers-new-hope-for-patients-with-metastatic-melanoma 2024-02-27T15:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/255bdf7632f92b22/greenwich-lifesciences-expands-flamingo-01-phase-iii-clinical-trial-to-europe 2024-02-27T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3c697a7053c96942/memorial-sloan-kettering-cancer-center-now-enrolling-patients-in-phase-1-2-clinical-trial-of-imunons-imnn-001-in-combination-with-bevacizumab-in-advanced-ovarian-cancer 2024-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/760f847fe3444b89/antibody-reduces-allergic-reactions-to-multiple-foods-in-nih-clinical-trial 2024-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/934659e94e0846e8/pcm-trials-acquires-emvenio-research-to-expand-decentralized-clinical-trial-access-for-underrepresented-communities 2024-02-26T10:40:40+00:00 weekly 0.7 https://trial.medpath.com/news/ddbf0167ab737179/global-rare-disease-crisis-3-5-million-uk-patients-face-critical-healthcare-challenges 2024-02-26T01:31:54+00:00 weekly 0.7 https://trial.medpath.com/news/d95091cbf5629e19/thervacb-therapeutic-vaccine-begins-first-in-human-trial-for-chronic-hepatitis-b 2024-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/134999e1ffda02f4/fda-analysis-reveals-decade-of-growth-in-rare-pediatric-disease-drug-development-through-priority-review-voucher-program 2024-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a5a640d5930f45e0/combination-therapy-shows-promise-for-chronic-gvhd-as-real-world-data-confirms-ruxolitinib-s-sustained-activity 2024-02-24T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b72c780e530f5973/intrommune-therapeutics-presents-supporting-data-introducing-a 2024-02-23T23:22:33+00:00 weekly 0.7 https://trial.medpath.com/news/a1b3c13ddacefd09/experts-highlight-key-trends-and-challenges-in-rare-disease-drug-development-for-2024 2024-02-23T07:24:50+00:00 weekly 0.7 https://trial.medpath.com/news/814854e3b7738274/darolutamide-shows-promising-results-in-treating-metastatic-hormone-sensitive-prostate-cancer 2024-02-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/65ffcec05c89fc78/fda-grants-orphan-drug-designations-to-two-novel-aml-therapies 2024-02-22T16:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/23b2b7ab139a9950/revolutionary-car-t-cell-therapy-offers-new-hope-for-autoimmune-disease-patients 2024-02-22T11:24:52+00:00 weekly 0.7 https://trial.medpath.com/news/c092902260b8bc60/indian-pharmaceutical-giants-race-to-develop-generic-versions-of-wegovy-as-global-weight-loss-market-approaches-100-billion 2024-02-22T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/55affb6764f9fb9f/moderna-pivots-beyond-covid-19-with-rsv-vaccine-launch-reports-better-than-expected-q4-profits 2024-02-22T03:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/22405626da5ed7e1/fda-gives-a-mixed-response-to-a-petition-seeking-greater-clinical-trial-transparency 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9eb8b2110648e9a5/india-s-indigenous-car-t-cell-therapy-revolutionizes-cancer-treatment-at-one-tenth-global-cost 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/738bc8a256f62c08/gsk-acquires-boston-pharmaceuticals-efimosfermin-for-liver-disease-in-2-billion-deal 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/81ee3d66e52ce867/evaluation-of-an-artificial-intelligence-based-clinical-trial-matching-system-for-hepatocellular-carcinoma 2024-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/86e10f0edcd9e77d/clinical-hold-on-studies-of-zelnecirnon-rpt193-in-atopic 2024-02-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2376f9fa6a91bd47/spectral-medical-announces-amendment-and-extension-of-exclusive-supply-and-distribution-agreement-with-baxter-healthcare-corporation-financial-post 2024-02-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3d74e85a1602762a/immuneering-shares-rise-after-fda-fast-track-status-for 2024-02-20T14:54:06+00:00 weekly 0.7 https://trial.medpath.com/news/21ff7e5c4dfbe251/roche-s-glofitamab-expands-treatment-horizons-for-multiple-b-cell-lymphomas 2024-02-20T10:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/9f101ca03ed46782/atropos-health-and-seqster-partner-to-revolutionize-healthcare-data-analytics-with-ai-powered-patient-registries 2024-02-20T03:45:44+00:00 weekly 0.7 https://trial.medpath.com/news/173ddeb94ed21280/astrazeneca-gets-new-tagrisso-ok-as-drug-succeeds-in 2024-02-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e337c8184f70f80c/cyclarity-therapeutics-advances-in-developing-a-plaque-busting-molecule-for-atherosclerosis 2024-02-19T11:53:39+00:00 weekly 0.7 https://trial.medpath.com/news/52d4ae5d033032a4/next-generation-clinical-data-management-systems-revolutionize-biotech-trials 2024-02-19T05:22:12+00:00 weekly 0.7 https://trial.medpath.com/news/b43ab6dd6021f02c/largest-covid-vaccine-study-yet-finds-links-to-health-conditions-bloomberg 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f3e0755633ebd483/datopotamab-deruxtecan-biologics-license-application-accepted-in-the-us 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1fd60f1ee144d300/houtou-jianweiling-tablet-shows-promise-in-treating-chronic-non-atrophic-gastritis 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4abeccbbaaac650d/double-blind-trial-shows-comparable-efficacy-in-treatment-and-control-groups-for-gastric-symptoms 2024-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/993ce7794182b645/fda-approves-osimertinib-plus-chemo-for-egfr-mutated-nsclc 2024-02-16T21:54:27+00:00 weekly 0.7 https://trial.medpath.com/news/64051f0ecf0f9dc8/fda-grants-orphan-drug-designation-to-tigilanol-tiglate-for-soft-tissue-sarcoma-treatment 2024-02-16T18:12:11+00:00 weekly 0.7 https://trial.medpath.com/news/72960733b0deb676/als-drug-from-denali-sanofi-falls-short-in-mid-stage-study 2024-02-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d8a4caaf634bfffd/nexicart-1-safety-and-efficacy-of-nxc-201-in-al-amyloidosis 2024-02-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/41ac3da12e63e6ff/adi-peg20-quadruples-three-year-survival-in-phase-3-mesothelioma-trial 2024-02-15T16:26:00+00:00 weekly 0.7 https://trial.medpath.com/news/7d4d6bb09bcace45/scope-summit-2024-patient-centricity-and-ai-drive-clinical-trial-innovation 2024-02-15T07:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/71370aad9ae99577/spectral-medical-announces-major-milestone-by-reaching-its-interim-enrollment-target-of-90-patients-financial-post 2024-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/286654fb0ef0e5d0/clinical-outcomes-before-and-after-prucalopride-treatment-an 2024-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/599ba1bfc5c5c9e6/neoadjuvant-chemohormonal-therapy-shows-promise-for-high-risk-prostate-cancer 2024-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8d7686d15285e063/ai-set-to-transform-drug-development-landscape-in-2024-from-clinical-trials-to-supply-chain-optimization 2024-02-14T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/99142cef944d4513/grifols-biotest-achieves-phase-3-success-for-fibrinogen-concentrate-in-acquired-deficiency-treatment 2024-02-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/266e7d6100804300/publication-in-diabetologia-highlights-ai-s-potential-for-type-1 2024-02-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/42ea0e8860daa47d/st-jude-scientists-develop-novel-bispecific-car-t-design-to-combat-acute-myeloid-leukemia-relapse 2024-02-13T14:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/46bfa5e979160907/fda-embraces-ai-integration-in-clinical-trials-while-emphasizing-safety-and-guidance 2024-02-13T13:43:38+00:00 weekly 0.7 https://trial.medpath.com/news/95d36beb0cb9bfdc/pasithea-therapeutics-announces-enrollment-opening-for-pas-004-phase-1-clinical-trial 2024-02-13T07:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/09c91b65932f9f43/hmnc-brain-health-advances-precision-psychiatry-with-novel-oral-ketamine-study-for-treatment-resistant-depression 2024-02-13T03:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/21ee984fdb472fd7/cancer-immunotherapy-treatment-options 2024-02-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4268bd852c77d7a4/fda-grants-fast-track-designation-to-gsk-s-bepirovirsen-for-chronic-hepatitis-b-treatment 2024-02-12T16:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/e7d675f320c27a40/ai-in-clinical-trials-industry-leaders-call-for-balanced-approach-at-scope-summit-2024 2024-02-12T13:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/fe60e7d4d254a69b/biotech-stock-roundup-mrna-s-q4-results-rapt-down-on-study-results-other 2024-02-12T13:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/2302caebe932c5c4/real-world-outcomes-of-advanced-renal-cell-carcinoma-treatment-with-immune-oncology-combinations 2024-02-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4032f85bec192546/4dmt-presents-interim-data-from-4d-310-inglaxa-phase-1-2-clinical-trials-for-fabry-disease-cardiomyopathy-at-worldsymposiumtm-2024 2024-02-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/647919055d298bef/5-year-survival-outcomes-in-bladder-cancer-treatment-study 2024-02-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3e1fb906cdfd56a1/takeda-advances-tak-861-to-phase-iii-for-narcolepsy-type-1-following-positive-phase-iib-results 2024-02-09T13:51:12+00:00 weekly 0.7 https://trial.medpath.com/news/c326a5cbb59e7aff/oral-serds-a-new-hope-for-metastatic-breast-cancer-treatment 2024-02-07T19:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/7a18a45198c5e16c/byondis-advances-novel-her2-targeting-adc-trastuzumab-duocarmazine-in-multiple-cancer-indications 2024-02-07T18:42:04+00:00 weekly 0.7 https://trial.medpath.com/news/a483712f1cbc5be8/mindmed-advances-lsd-development-program-for-major-depressive-disorder-treatment 2024-02-07T18:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/031526ceec34529d/cytomx-therapeutics-reports-promising-interim-phase-1-data-for-cx-2051-antibody-drug-conjugate 2024-02-07T16:43:08+00:00 weekly 0.7 https://trial.medpath.com/news/d22b22787b52fde5/long-term-efficacy-and-safety-of-iptacopan-in-pnh-with-anaemia 2024-02-07T13:56:30+00:00 weekly 0.7 https://trial.medpath.com/news/b50c48691ca7e8ad/nhs-england-launches-brca-testing-program-for-jewish-community-to-combat-cancer-risk 2024-02-07T03:43:45+00:00 weekly 0.7 https://trial.medpath.com/news/ce30b2f7feb009fb/iterum-therapeutics-upgraded-to-buy-on-successful-trial-by-investing-com 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dd6225ee6950e9a2/lb-pharmaceuticals-advances-schizophrenia-treatment-with-lb-102 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ede88840e44eb14f/fda-grants-latozinemab-breakthrough-therapy-designation-for-frontotemporal-dementia-due-to-a-progranulin-gene-mutation-ftd-grn 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/66f0cf42ccdeea6f/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule 2024-02-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1666e60b11b3bd5b/fda-grants-fast-track-status-to-vepdegestrant-for-er-her2-metastatic-breast-cancer 2024-02-06T18:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/834a85bac5d31dda/eu-clinical-trials-regulation-advances-harmonization-with-2025-transition-deadline 2024-02-06T04:27:23+00:00 weekly 0.7 https://trial.medpath.com/news/5682d9d7332c0d0f/metagenomi-aims-for-87m-ipo-to-advance-novel-gene-editing-platform 2024-02-06T00:05:49+00:00 weekly 0.7 https://trial.medpath.com/news/16b03c4b46e347d3/fda-grants-fast-track-designation-to-bnt325-db-1305-for-platinum-resistant-ovarian-cancer 2024-02-05T22:18:47+00:00 weekly 0.7 https://trial.medpath.com/news/82c13e2d2af33480/j-j-s-nipocalimab-shows-promise-in-treating-autoimmune-diseases 2024-02-05T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/5fe81cecb70bf62e/fda-panel-recommends-new-standards-for-pulse-oximeters-amid-bias 2024-02-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/555812c4ba480b84/mpox-treatment-niaid-national-institute-of-allergy-and-infectious 2024-02-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3867c7a4b7f1542d/aviceda-begins-part-2-of-phase-ii-iii-trial-for-geographic-atrophy 2024-02-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/06a030eb2bba718c/cabaletta-bio-announces-fda-granted-orphan-drug 2024-02-01T16:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/97ef17a5ee76af77/proniras-secures-4-65-in-series-b-financing 2024-02-01T15:14:22+00:00 weekly 0.7 https://trial.medpath.com/news/9b53b85b3074de09/new-treatment-hope-for-blood-cancer-patients 2024-02-01T12:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/7ff535188f11ec5e/merck-signals-continued-pursuit-of-15b-deals-to-offset-future-keytruda-patent-loss 2024-02-01T03:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/395bff4b0c2f1940/usher-syndrome-market-insight-epidemiology-and-market-forecast-2034 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/835b3ee73239e197/a-clinical-trial-is-launched-for-a-novel-drug-that-could-extend 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/06a68d4694bc1e81/fda-revokes-euas-for-four-monoclonal-antibody-products 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8d83fecda2afa1e1/real-world-use-of-fedratinib-for-myelofibrosis-following-ruxolitinib-failure 2024-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9387d36f8764051a/adaptimmune-announces-u-s-fda-acceptance-of-biologics-license-application-for-afami-cel 2024-01-31T16:44:00+00:00 weekly 0.7 https://trial.medpath.com/news/69c8e7c3798072e2/alnylam-advances-zilebesiran-to-phase-3-cardiovascular-outcomes-trial-following-positive-kardia-3-results 2024-01-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/72a57027c8ca7b6f/curiteva-receives-fda-clearance-for-world-s-first-3d-printed-trabecular-peek-lumbar-fusion-system 2024-01-30T12:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/00c21730a6278b96/fda-grants-orphan-drug-designation-to-neoimmunetech-s-nt-i7-for-advanced-pancreatic-cancer-treatment 2024-01-30T06:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/8065314f3f5ac9a8/bayer-s-high-dose-eylea-8mg-aflibercept-accepted-for-review-by-china-s-nmpa-following-uk-approval 2024-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/65063bb343b591c8/experimental-pain-drug-may-offer-alternative-to-opioids-for-acute-pain-study-finds-cnn 2024-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/13f07b6705520fb6/scandion-oncology-reports-positive-phase-iia-data-in-corist-part-3-trial 2024-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a551afb87b3a13f6/enhertu-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumours 2024-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7b089a818b426ce8/sequana-medical-announces-fda-acceptance-for-substantive-review-of-the-premarket-approval-application-for-alfapump-r-in-recurrent-or-refractory-ascites-due-to-liver-cirrhosis 2024-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7a17e71c33dee335/first-patient-enrolled-in-rise-therapeutics-rheumatoid-arthritis 2024-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/190285adc8bc57e7/car-t-cell-therapy-shows-promise-in-reversing-age-related-metabolic-dysfunction 2024-01-28T17:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/e0072f586873f810/gene-therapy-trials-restore-hearing-to-children-born-deaf 2024-01-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5e3e0ccf86508bfd/bravyl-shows-promise-in-slowing-als-progression-study-finds 2024-01-26T12:24:54+00:00 weekly 0.7 https://trial.medpath.com/news/fc8aabc072b088d4/major-pharma-giants-unite-at-biophysics-for-drug-discovery-summit-to-advance-novel-therapeutic-development 2024-01-26T06:06:32+00:00 weekly 0.7 https://trial.medpath.com/news/128959e8ffb7411b/ema-confirms-recommendation-for-non-renewal-of 2024-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6853dc50fcee4ab7/generative-ai-set-to-transform-life-sciences-industry-in-2024-from-trust-building-to-personalized-medicine 2024-01-25T02:22:40+00:00 weekly 0.7 https://trial.medpath.com/news/fa5f9ed93fbd6f31/breakthrough-in-glioblastoma-treatment-research-at-mayo-clinic 2024-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b235fef9d0a8de5e/pembrolizumab-shows-significant-survival-benefit-in-adjuvant-therapy-for-kidney-cancer 2024-01-24T13:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/1643604a53fca3c1/experts-outline-new-approaches-to-combination-therapy-in-atopic-dermatitis-management 2024-01-23T06:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/6aa769d2d1fe6c6d/taiho-oncology-announces-publication-of-final-results-from-ascertain-clinical-trial 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/71718bc55f6568a1/first-line-nivolumab-plus-ipilimumab-shows-benefit-in 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a8b3949d65633f79/fda-approves-eflornithine-for-adult-pediatric-patients-with 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ba0cbcb410be6159/you-become-so-strong-duncan-b-c-family-enrolls-infant-son-in-clinical-trial-to-treat-leukemia 2024-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/14eba0af7ae28757/lixte-biotechnology-s-lb-100-shows-promise-in-multiple-cancer-indications-through-novel-pp2a-inhibition 2024-01-22T09:04:29+00:00 weekly 0.7 https://trial.medpath.com/news/e5134d557a814060/eli-lilly-s-ramucirumab-shows-promise-in-expanding-treatment-portfolio-for-laryngeal-cancer 2024-01-22T08:58:36+00:00 weekly 0.7 https://trial.medpath.com/news/7379efc4b7d339ac/pfizer-s-crizotinib-explores-new-frontier-in-her2-negative-breast-cancer-treatment 2024-01-22T08:56:56+00:00 weekly 0.7 https://trial.medpath.com/news/074c0c8bf783200a/merck-launches-phase-3-trial-testing-sacituzumab-tirumotecan-pembrolizumab-combination-in-high-risk-triple-negative-breast-cancer 2024-01-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b5f15d44b291fe76/superbug-crisis-phage-therapy-offers-hope-against-antibiotic-resistance 2024-01-21T15:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/2d5de2fcbf97c0b7/jacobio-pharma-presents-data-of-glecirasib-in-patients-with-pancreatic 2024-01-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3bcbf74146460b2d/stemcell-technologies-expands-clinical-capabilities-through-strategic-acquisitions-of-sqz-biotechnologies-and-propagenix 2024-01-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b2a5344f8c280375/domvanalimab-combination-shows-promise-in-first-line-gastroesophageal-cancer-treatment 2024-01-18T17:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/b5d51cc06f448360/fda-clears-neurosigma-s-second-generation-monarch-etns-system-for-pediatric-adhd-treatment 2024-01-18T05:26:02+00:00 weekly 0.7 https://trial.medpath.com/news/59ef026b4e2b1a89/early-treatment-in-weeks-after-hiv-infection-may-help-better-control-virus-long-term-study-finds-euronews 2024-01-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0622c1606de5129d/pepromene-bio-inc-announces-complete-remission-of-the-cohort-1-first-patient-treated-for-relapsed-and-refractory-b-cell-acute-lymphoblastic-leukemia-b-all-in-the-phase-1-clinical-trial-of-pmb-ct01-baffr-car-t-cells-at-city-of-hope 2024-01-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ab2cdf65034f4767/new-cancer-drug-offers-kinder-alternative-to-chemotherapy-for-children 2024-01-17T01:15:24+00:00 weekly 0.7 https://trial.medpath.com/news/dd34214eeebcfef5/maia-biotechnology-provides-positive-phase-2-clinical-updates-for-lead 2024-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a55f47bf9941b0ba/video-faricimab-shows-good-visual-stability-extended-healio 2024-01-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1ad726a338770c8e/global-bacteriophage-therapy-summit-to-address-clinical-development-challenges-in-boston 2024-01-16T08:00:47+00:00 weekly 0.7 https://trial.medpath.com/news/2024d2a93565cace/nurix-therapeutics-receives-u-s-fda-fast-track-designation-for-nx-5948 2024-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3dc1b26ceddac982/fda-approves-new-crispr-gene-editing-treatment 2024-01-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/08b3591ed51f2b0b/phase-3-trial-of-crinecerfont-shows-promise-in-treating-pediatric-congenital-adrenal-hyperplasia 2024-01-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a068b07c10951e2e/novel-protein-based-blood-test-achieves-90-accuracy-in-detecting-early-stage-cancers-across-18-tumor-types 2024-01-14T18:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/c019df1eab8c41f4/biosimilars-in-2024-market-evolution-promises-cost-savings-amid-industry-challenges 2024-01-14T05:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/acbaa1781f5ba852/alnylam-pharmaceuticals-reports-strong-financial-growth-and-advances-in-rnai-therapeutics 2024-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/12e485beeb58bbe0/key-trends-from-jp-morgan-2024-m-a-revival-ai-integration-and-adc-renaissance-in-pharma 2024-01-12T07:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/a5f2ffc4a6e9ec25/rh5-1-matrix-m-vaccine-shows-promising-efficacy-against-malaria-in-african-children 2024-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/611244e6258f5d83/phase-2-study-supports-second-line-axi-cel-in-r-r-lbcl-targeted-oncology 2024-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2a9f195c372999d7/nafdac-launches-electronic-clinical-trial-application-platform 2024-01-11T09:03:19+00:00 weekly 0.7 https://trial.medpath.com/news/48fc7af7b67090e4/life-sciences-real-estate-sector-faces-four-key-challenges-in-2024-sustainability-funding-and-market-evolution 2024-01-11T01:59:15+00:00 weekly 0.7 https://trial.medpath.com/news/7c8403a2154ecfc7/the-european-medicines-agency-s-scientific-advisory-group 2024-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3d354cd23ff47bf7/study-evaluates-impact-of-adjuvant-chemotherapy-on-ipmn-derived-pancreatic-ductal-adenocarcinoma 2024-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f583917f54054195/study-confirms-safety-and-efficacy-of-houtou-jianweiling-tablet-for-chronic-non-atrophic-gastritis 2024-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f2c8c43eacd14efb/bispecific-antibodies-promising-advances-amid-adoption-challenges-in-cancer-treatment 2024-01-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/485b258558f7742e/pharmather-sets-august-2025-fda-approval-goal-date-for-ketamine-product-confirms-full-funding-through-commercial-launch 2024-01-10T12:32:36+00:00 weekly 0.7 https://trial.medpath.com/news/ea18ff064febe33e/ai-and-advanced-technologies-reshape-clinical-trial-design-and-development-strategy 2024-01-10T04:13:59+00:00 weekly 0.7 https://trial.medpath.com/news/549c756c3d6d21a7/novavax-advances-global-vaccine-development-with-protein-based-platform-and-matrix-m-technology 2024-01-10T02:34:36+00:00 weekly 0.7 https://trial.medpath.com/news/131c795f3dd1c3f8/five-key-pharma-marketing-trends-reshaping-industry-strategy-in-2024 2024-01-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1cc87b2dca99bcac/elicio-s-eli-002-cancer-vaccine-shows-promising-results-in-phase-1-trial-for-pancreatic-and-colorectal-cancer 2024-01-10T00:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/e9a24000a899ba99/largest-study-to-date-of-high-dose-methotrexate-associated 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a2309cf82f51e0e0/adoption-of-total-neoadjuvant-therapy-in-the-treatment 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b8e836a161f8b3cf/ema-approves-first-ustekinumab-biosimilar-uzpruvo 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f073b7a8d7ac7d89/first-patient-dosed-in-phase-iii-prostact-global-study-of 2024-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9ad55a4d8f321191/adimab-announces-2023-clinical-pipeline-update-with-12-new-partner-programs 2024-01-09T19:18:47+00:00 weekly 0.7 https://trial.medpath.com/news/f54398c4a5e59949/quanthealth-secures-17m-series-a-funding-to-advance-ai-powered-clinical-trial-simulations 2024-01-09T02:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/07806a69efc85456/gsk-acquires-aiolos-bio-for-1-4b-expanding-asthma-treatment-portfolio-with-novel-tslp-inhibitor 2024-01-09T01:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/42072c6833b2ab79/doxycycline-post-exposure-prophylaxis-shows-promise-in-reducing-stis-among-msm 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e4af33ff263869f4/genascence-advances-first-gene-therapy-for-knee-osteoarthritis-in-phase-1b-donatello-trial 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/62dc25e3256f0b1c/real-world-study-highlights-adverse-events-associated-with-lenvatinib-use 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2680e5f323144ea0/disitamab-vedotin-shows-promising-results-in-advanced-urothelial-carcinoma-treatment-at-2024-esmo-congress 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e8a063d83e5be1d2/fda-oks-nda-for-sh-105-in-breast-and-ovarian-cancer 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0f0e055bf08c38ad/mobile-application-reduces-opioid-misuse-after-cesarean-section 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd0de43ecda13689/innovent-s-mazdutide-achieves-phase-3-success-in-chinese-obesity-trial-paving-way-for-first-glp-1r-gcgr-dual-agonist-approval 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/af4993627b14a8f1/alnylam-s-amvuttra-shows-significant-cardiac-benefits-in-attr-amyloidosis-patients-at-acc-25 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3f379e70196a103d/glp-1-receptor-agonists-show-promise-for-weight-loss-in-overweight-and-obese-individuals-without-diabetes 2024-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7cfa1ffe56fffd5a/pharma-stock-roundup-fda-nod-to-azn-s-eplontersen-crl-to-mrk-s-cough-candidate 2024-01-08T22:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/9342706e36d5abb6/biotech-stock-roundup-biib-eisai-s-drug-update-nvax-gains-on-deal-amendment 2024-01-08T22:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/34d8da22aa60e8c9/biolinerx-ltd-nasdaq-blrx-q3-2023-earnings-call-transcript 2024-01-08T20:03:08+00:00 weekly 0.7 https://trial.medpath.com/news/d6c9dafcc543246c/new-covid-vaccines-ok-d-by-fda-escaped-convict-search-5-things-podcast 2024-01-08T15:45:22+00:00 weekly 0.7 https://trial.medpath.com/news/1a796b88e1140c19/geovax-labs-inc-nasdaq-govx-q3-2023-earnings-call-transcript 2024-01-08T13:04:51+00:00 weekly 0.7 https://trial.medpath.com/news/394966c6ff528d89/revolution-medicines-inc-nasdaq-rvmd-q3-2023-earnings-call-transcript 2024-01-08T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/3e8a6ca056b86a64/atai-life-sciences-nv-reports-q3-2023-financial-results-and-pipeline-progress 2024-01-08T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/6097bdec20d86d77/biotech-stock-roundup-aldx-evlo-down-on-setback-srrk-offers-updates-more 2024-01-08T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/9c195ca5ac86ff3f/eli-lilly-novo-nordisk-stocks-soar-after-weight-loss-drug-trial-boosts-outlook 2024-01-08T12:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/a5918650296f4200/mereo-biopharma-updates-on-pipeline-progress-and-corporate-developments 2024-01-08T12:06:13+00:00 weekly 0.7 https://trial.medpath.com/news/933b308cfeb20176/bristol-myers-bmy-nsclc-drug-application-gets-ema-validation 2024-01-08T12:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/58aa2f30d751d6e4/noddy-holders-secret-throat-cancer-battle-as-wife-reveals-singer-was-told-he 2024-01-08T11:10:10+00:00 weekly 0.7 https://trial.medpath.com/news/247b34329fac22a0/fluoguide-advances-fg001-development-for-cancer-surgery-precision 2024-01-08T11:06:07+00:00 weekly 0.7 https://trial.medpath.com/news/d1f6737939f1c594/inspira-iinn-advances-foothold-in-europe-with-extended-deal 2024-01-08T11:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/9b57c81373a661d3/karyopharm-announces-preliminary-unaudited-2023-revenue-and-2024-objectives 2024-01-08T08:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/8ce1660820d7cd76/diamyd-medical-gains-market-research-findings-to-guide-us-commercial-strategy 2024-01-08T08:28:00+00:00 weekly 0.7 https://trial.medpath.com/news/70d72c1ab14be659/ensysce-biosciences-highlights-2023-achievements-and-plans-for-2024 2024-01-08T08:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/607c36e6398b328f/j-j-acquires-ambrx-for-2b-to-expand-antibody-drug-conjugate-portfolio-in-oncology 2024-01-08T01:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/bd04a642e9bff79e/fda-grants-soligenix-orphan-drug-designation-for-dusquetide-in-behcet-s-disease-treatment 2024-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ec9b76000d23769f/abbvie-s-lutikizumab-shows-promise-in-phase-2-trial-for-hidradenitis-suppurativa-advances-to-phase-3 2024-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7395134a39bde203/nurix-therapeutics-outlines-2024-strategic-priorities-with-focus-on-cancer-and-autoimmune-diseases 2024-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3a3914ffd40ae85e/curevo-vaccine-announces-positive-phase-2-trial-results-for-next-generation-shingles-vaccine 2024-01-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ca0fff8836f0cece/eli-lilly-disrupts-drug-access-with-lillydirect-new-telehealth-platform-for-obesity-and-chronic-disease-medications 2024-01-07T00:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/8db0a1bec837fe28/ascendis-pharma-unveils-vision-2030-strategic-roadmap 2024-01-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5a0c2bb17a686eae/new-drug-application-submitted-for-journey-medicals-rosacea-candidate 2024-01-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9000813b28f80bfa/ultragenyx-announces-preliminary-2023-revenue-and-2024-financial-guidance 2024-01-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b6904172e91ba2b4/acupuncture-shows-promise-in-treating-combat-related-ptsd 2024-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6d1ba29bd9afb32a/allogene-therapeutics-pivots-strategy-with-pipeline-restructuring-and-22-workforce-reduction 2024-01-05T15:56:48+00:00 weekly 0.7 https://trial.medpath.com/news/c6c844596102c7db/combat-veterans-took-a-psychedelic-drug-for-ptsd-then-this-happened 2024-01-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3d9a6f8d0a01d6bd/intellia-announces-workforce-reduction-and-research-pause 2024-01-04T17:47:00+00:00 weekly 0.7 https://trial.medpath.com/news/deafa1ed73c2ebf8/askbio-s-ab-1005-gene-therapy-for-parkinsons-disease-meets-primary-endpoint-in-phase-ib-trial 2024-01-04T13:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/995677f24fb2dc08/newamsterdam-pharma-announces-2024-strategic-priorities-and-clinical-trial-updates 2024-01-04T13:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/c15b32f8d8d83559/quanta-therapeutics-advances-kras-directed-drug-candidates-with-fda-ind-clearance 2024-01-04T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/41688eb9757e02b2/autolus-advances-obecabtagene-autoleucel-car-t-therapy-for-relapsed-refractory-all 2024-01-04T10:08:42+00:00 weekly 0.7 https://trial.medpath.com/news/cf21f87b52b120aa/patient-voice-amplification-critical-for-clinical-trial-success-industry-analysis-shows-85-retention-failure-rate 2024-01-04T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f4bbc072f0b84c9c/accords-bla-for-its-ustekinumab-stelara-r-biosimilar-accepted-by-fda-settlement-with-janssen-permits-launch-by-15-may-2025-pearce-ip 2024-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0856e2460aa54654/zymeworks-outlines-strategic-priorities-and-outlook-for-2024-and-2025 2024-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0814efbaf581011c/upstream-bio-advances-verekitug-into-phase-2-trials-for-severe-asthma-and-chronic-rhinosinusitis-with-nasal-polyps 2024-01-03T12:06:18+00:00 weekly 0.7 https://trial.medpath.com/news/24acb3bd686baf38/obesity-drug-market-surges-major-pharma-companies-race-to-develop-novel-treatments 2024-01-03T02:13:03+00:00 weekly 0.7 https://trial.medpath.com/news/3dbfcdc5ae73f031/tonix-pharmaceuticals-to-present-at-two-upcoming-investor 2024-01-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/28e1e016de6c5251/henlius-to-release-clinical-data-at-2024-asco-gi 2024-01-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d3040265e1d40555/j-j-s-lung-cancer-therapy-succeeds-in-head-to-head-study-with-lcfa 2024-01-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/536aec1948bf085f/spero-therapeutics-initiates-phase-3-trial-for-first-oral-carbapenem-in-us-targeting-complicated-utis 2024-01-02T13:42:43+00:00 weekly 0.7 https://trial.medpath.com/news/abff55560c7290c8/pasithea-therapeutics-announces-fda-acceptance-of-ind-application-for-pas-004-in-advanced-cancer-patients 2024-01-02T13:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/27cc5dcb32e1fd05/syndax-pharmaceuticals-announces-key-updates-and-2024-milestones 2024-01-02T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/30ca2b2ad0799628/mit-develops-wireless-implantable-device-for-continuous-insulin-production-in-type-1-diabetes 2024-01-02T02:02:14+00:00 weekly 0.7 https://trial.medpath.com/news/79f40763f89b7774/4sc-ag-receives-paediatric-investigation-plan-waiver 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b39a71b239e84a11/fda-requires-guillain-barre-syndrome-gbs-warning-in 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/66cd5c9f1e9f89fb/fda-grants-priority-review-for-cutx-101-in-treatment-of-menkes-disease 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ccf57401777f6231/early-intervention-treatment-in-the-first-2-weeks-following-concussion 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/60b9dd3d9decee58/pynnacle-study-rezatapopt-pynnacle-clinical-study 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/58b9450d2ee0f836/annovis-bio-announces-positive-fda-notice-for 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7aafcedea8fd2ad1/neoadjuvant-chemotherapy-plus-camrelizumab-shows-promise-for-locally-advanced-cervical-cancer 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/21fc419e6b21f50b/cryptosporidium-pi-4-k-inhibitor-edi048-is-a-gut-restricted 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/db8f1df1b372286a/sabcs-2024-highlights-advances-in-breast-cancer-treatment 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1bd9fe545668b1cb/apogee-s-apg777-shows-75-day-half-life-in-phase-1-trial-for-atopic-dermatitis 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/39c36fe10a1ed4fa/measurable-residual-disease-assessment-prior-to 2024-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/22f1b8ae89a564a0/pirtobrutinib-shows-high-response-rates-in-relapsed-cll-patients-with-btk-mutations 2023-12-28T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d21bb954177e3ac6/sequana-medical-submits-premarket-approval-application-to-us-fda-for 2023-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/507f50ea28775556/ai-assisted-colonoscopy-boosts-adenoma-detection-rate-by-40-in-junior-endoscopists 2023-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4db1ab8e72e3344d/landmark-phase-3-mariposa-study-meets-primary 2023-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c3a3234b0388904a/bms-acquires-karuna-therapeutics-for-14-billion-betting-on-novel-schizophrenia-drug-karxt 2023-12-23T08:49:46+00:00 weekly 0.7 https://trial.medpath.com/news/92a51b593156c979/u-s-food-and-drug-administration-issues-complete-response-globenewswire 2023-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5137b41003757ea2/fujirebio-launches-automated-ptau-217-plasma-assay-for-alzheimer-s-disease-research 2023-12-22T17:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/7ccf49f70595791b/patritumab-deruxtecan-granted-priority-review-in-the-u-s-for-egfr-mutated-non-small-cell-lung-cancer-treatment 2023-12-22T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/55539f8744c71543/arch-biopartners-advances-to-phase-ii-trial-for-cs-aki-treatment-in-turkey 2023-12-21T12:33:43+00:00 weekly 0.7 https://trial.medpath.com/news/350051eea95e1bc0/biosimilar-market-set-for-major-expansion-in-2024-ophthalmology-and-immunology-lead-growth 2023-12-21T09:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/88c3fc6f60a5c558/maat-pharma-advances-microbiome-therapeutics-in-oncology 2023-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6072acaa12c1ca44/mindbio-therapeutics-ceo-updates-on-phase-2-clinical-trials-progress 2023-12-20T11:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/f6ff411becd486eb/bayer-s-radium-223-dichloride-expands-treatment-horizons-for-metastatic-prostate-cancer 2023-12-20T10:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/e1c3a84f11f42b0c/evolution-of-treatment-landscape-shows-improved-survival-in-metastatic-colorectal-cancer 2023-12-20T10:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/ecb2c801eb2ef350/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093-gsk 2023-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7c3d081a7b6a7565/passage-bio-reports-preliminary-data-from-ftd-grn-gene-therapy-trial 2023-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4978a5cee4b7adef/depression-and-cancer-how-psilocybin-from-mushrooms-can-help 2023-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c8dbc9a9a4e7de1f/bridging-therapy-responses-may-outcomes-with-axi-cel 2023-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8d013dfb4cb0454e/revive-therapeutics-advances-bucillamine-development-for-long-covid-treatment-through-manufacturing-partnership 2023-12-18T12:06:10+00:00 weekly 0.7 https://trial.medpath.com/news/1363ad6fce67b0d5/ai-text-analytics-revolutionizes-clinical-trial-data-processing-and-patient-assessment 2023-12-18T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/904d809a60d7879a/chinese-drug-sunvozertinib-shows-record-61-response-rate-against-rare-lung-cancer 2023-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9f06a7bd72736b80/pembrolizumab-plus-lenvatinib-fails-to-meet-survival-endpoints-in-advanced-endometrial-cancer 2023-12-15T16:02:06+00:00 weekly 0.7 https://trial.medpath.com/news/e36ffb7638c99808/fda-approves-merck-s-welireg-for-advanced-kidney-cancer-expanding-treatment-options 2023-12-15T11:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/d4edc767a7347c0c/nihr-hosts-expert-panel-on-advancing-equality-and-diversity-in-clinical-research 2023-12-15T09:02:42+00:00 weekly 0.7 https://trial.medpath.com/news/f6b81da1267e4f30/acadia-pharmaceuticals-secures-two-key-patent-victories-for-parkinson-s-drug-nuplazid 2023-12-14T02:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/ec577211d4b1fec2/spectral-medical-provides-tigris-trial-update 2023-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/46b66c4c8eacfe08/checkmate-77t-trial-shows-perioperative-nivolumab-significantly-improves-event-free-survival-in-resectable-nsclc 2023-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c6e9ab0f35873acf/halia-therapeutics-initiates-phase-2a-trial-of-first-in-class-nlrp3-inhibitor-ht-6184-for-lower-risk-myelodysplastic-syndromes 2023-12-13T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6d2eaa108e85af24/fda-approves-eflornithine-to-reduce-risk-of-relapse-in 2023-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aee6ef154220ddbb/talquetamab-dose-reductions-maintain-efficacy-while-reducing-toxicities-in-relapsed-refractory-multiple-myeloma 2023-12-12T15:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/6070bbbd7dcad794/gc-biopharma-secures-44-million-who-flu-vaccine-contract-and-partners-with-canadian-firm-for-mrna-development 2023-12-12T10:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/24ab10e3683774b5/plexium-advances-first-in-class-ikzf2-degrader-plx-4545-into-phase-1-clinical-trial 2023-12-12T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0f212c235e94abf6/irlab-strengthens-patent-protection-for-pirepemat-a-novel-parkinson-s-fall-prevention-therapy 2023-12-12T06:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/892169a099c04649/first-in-human-clinical-trial-of-car-t-cell-therapy-with-new 2023-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/643b93fa3771a5fc/second-line-axi-cel-prolongs-survival-over-standard 2023-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ecfe290e14bf5206/hope-3-trial-of-dmd-therapy-cap-1002-to-continue-as-planned 2023-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2aeeb6db9bf7ea1d/iptacopan-yields-hematological-improvements-in-pnh-persistent-anemia 2023-12-11T18:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/97d868e95eac2417/moleculin-s-annamycin-shows-36-complete-response-rate-in-aml-phase-1b-2-trial-with-zero-cardiotoxicity 2023-12-11T13:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/13afdd045ceda90d/merck-and-moderna-initiate-phase-3-study-for-adjuvant-treatment-of-non-small-cell-lung-cancer 2023-12-11T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/9453e1d54680163e/isatuximab-combination-therapy-achieves-superior-mrd-negativity-rates-in-newly-diagnosed-multiple-myeloma 2023-12-11T03:22:20+00:00 weekly 0.7 https://trial.medpath.com/news/d7fbe7e95195306f/evaluation-of-self-sampling-based-cervical-cancer-screening-strategy-during-covid-19-pandemic 2023-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e439a1a055af54e8/abbvie-advances-two-novel-b-cell-lymphoma-therapies-in-first-in-human-trials 2023-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/53afe29dc245da77/chinese-herbal-injections-combined-with-platinum-based-chemotherapy-improve-outcomes-in-advanced-non-small-cell-lung-cancer 2023-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/01c848bce32c6005/taiho-oncology-presents-real-world-study-data-on-oral-decitabine-and-cedazuridine-for-mds 2023-12-10T15:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/97b56e27ce09e697/updated-odronextamab-data-from-relapsed-refractory-diffuse-globenewswire 2023-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/657055d47e593a24/neoadjuvant-pembrolizumab-plus-chemotherapy-shows-sustained-survival-benefit-in-early-stage-tnbc 2023-12-09T14:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/aa4ef7a45bd2cecd/south-korea-advances-real-world-evidence-integration-in-drug-development-and-regulatory-decision-making 2023-12-08T14:37:32+00:00 weekly 0.7 https://trial.medpath.com/news/6b3c18f70816c2bf/solid-biosciences-sldb-dmd-drug-gets-fast-track-tag-stock-up 2023-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/34bb0e38b4068abb/advancing-rare-cancer-treatment-through-home-run-clinical-trials 2023-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/31fc6608f4d3dbbe/u-s-fda-grants-priority-review-for-elafibranor-a-potential-new-treatment-for-primary-biliary-cholangitis 2023-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/610b17ea33ac8b02/jacobio-pharma-to-present-data-of-kras-g12c-inhibitor-glecirasib-in 2023-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b3a2a7b201f76d03/novartis-receives-fda-approval-for-fabhalta-r-iptacopan-offering-superior-hemoglobin-improvement-in-the-absence-of-transfusions-as-the-first-oral-monotherapy-for-adults-with-pnh-novartis 2023-12-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dcce5327c458e1b9/fda-grants-tar-200-breakthrough-therapy-designation-for-bcg-unresponsive-nmibc 2023-12-05T17:53:00+00:00 weekly 0.7 https://trial.medpath.com/news/ddd0b5df5712bc21/neurocrine-biosciences-receives-breakthrough-therapy-designation-from-u-s-food-and-drug-administration-for-crinecerfont-in-congenital-adrenal-hyperplasia 2023-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/005fcc3730aee817/brainchild-bio-spins-out-of-seattle-children-s-to-develop 2023-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0f05066b982efa03/travere-therapeutics-advances-filspari-toward-fda-approval-following-pre-nda-meeting 2023-12-04T21:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/f915b03846db8c00/rapt-therapeutics-announces-positive-results-from-phase-1a-1b-clinical-trial-of-zelnecirnon-for-atopic-dermatitis 2023-12-04T20:51:36+00:00 weekly 0.7 https://trial.medpath.com/news/645648a459761ad7/roche-acquires-carmot-therapeutics-for-2-7-billion-to-enter-obesity-drug-market 2023-12-04T11:13:58+00:00 weekly 0.7 https://trial.medpath.com/news/ee65ec7f50552cda/bms-advances-ipilimumab-development-for-metastatic-pancreatic-adenocarcinoma 2023-12-04T08:58:58+00:00 weekly 0.7 https://trial.medpath.com/news/f4359569487ad03b/elevidys-makes-history-as-first-gene-therapy-for-dmd-but-challenges-remain 2023-12-04T07:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/75ae4b026ddf6f70/novel-treatment-landscape-expands-for-uveal-melanoma-with-multiple-promising-therapies-in-development 2023-12-04T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0269d69f98cd9022/esmo-asia-congress-2023-oncologypro 2023-12-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fa4c99693f17b7f0/optimizing-outcomes-for-high-risk-non-muscle-invasive-bladder-cancer-with-pd-l-1-inhibitors 2023-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/769e3db52995ac4f/the-rising-importance-of-real-world-data-and-evidence-in-pharmaceutical-r-d 2023-11-30T23:29:21+00:00 weekly 0.7 https://trial.medpath.com/news/eb86c981bf214842/novartis-secures-1-3-billion-deal-with-chong-kun-dang-for-hdac6-inhibitor-targeting-cmt-disease 2023-11-30T20:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/f5cc127e6e4c61d3/acadia-pharmaceuticals-launches-phase-3-compass-pws-trial-for-carbetocin-nasal-spray-in-prader-willi-syndrome 2023-11-30T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/dccfeba243e34752/clarity-s-64cu-sar-bispsma-shows-promise-in-detecting-prostate-cancer-recurrence-in-cobra-trial 2023-11-30T00:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/3a92871368b1c1e7/fresenius-kabi-and-formycon-announce-fda-submission-for-fyb202-a-ustekinumab-biosimilar-candidate 2023-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/673457d049e00f19/cretostimogene-grenadenorepvec-monotherapy-first-cg-oncology 2023-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d16bd3dbd11f9059/takeda-janssen-join-wearable-maker-to-measure-scratching-and-other-health-tech-news 2023-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5e26e749c5bc9b24/an-anti-aging-drug-for-dogs-may-be-on-the-market-as-soon-as-2026-cbs-los-angeles 2023-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b98ce600d48acc77/oncosil-initiates-pancosil-trial-testing-percutaneous-delivery-of-radioactive-microparticles-for-pancreatic-cancer 2023-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1700d6f2b5e6dbc6/why-is-inflammation-disease-focused-acelyrin-stock-trading-lower-today-markets-insider 2023-11-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/52e356eceef31db6/crispr-cas9-technology-revolutionizes-car-t-cell-therapy-enhancing-efficacy-and-overcoming-treatment-barriers 2023-11-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b8ff869de1879592/gsk-reports-blenrep-outperforms-in-phase-iii-multiple-myeloma-trial 2023-11-27T08:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/8338ebe5653c2294/rpt193-demonstrates-greater-improvements-in-clinical 2023-11-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/19fc8cf7607b77b7/the-transformative-potential-of-immunotherapy-for-glioblastoma-patients 2023-11-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/03f8b64e1b4cbd09/dxvx-advances-licensing-deal-for-ovm-200-cancer-vaccine-in-asian-markets 2023-11-24T14:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/cce34e75a1dde526/astrazeneca-secures-kras-g12d-inhibitor-in-419m-deal-with-usynova 2023-11-23T08:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/0f209c96deab860c/phase-iib-trial-evaluates-efficacy-and-safety-of-anyu-peibo-capsules-for-major-depressive-disorder 2023-11-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fc070e348284f5b1/digital-health-measures-gain-traction-in-value-based-healthcare-despite-implementation-challenges 2023-11-21T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/69e5415b5c773467/immix-biopharma-announces-fda-approval-of-ind-application-for-car-t-nxc-201-enabling-u-s-patient-dosing-biospace 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a7e658f674ef2bee/aimovig-demonstrates-superior-tolerability-and-efficacy-over-topiramate-in-first-head-to-head-migraine-prevention-study 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5fd5c5f72ce08e54/connect-biopharma-partners-with-simcere-for-rademikibart-development-in-greater-china 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/da7da48e17c017b5/final-data-from-phase-iia-corist-part-2-trial-shows-promising-median-overall-survival-of-10-4-months 2023-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0a9781792320b2de/promis-neurosciences-initiates-phase-1a-clinical-trial-for-alzheimer-s-disease-treatment 2023-11-20T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8f79ed4a4eb2fb0d/asx-health-stocks-4dx-jumps-15pc-after-fda-clearance 2023-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f60fe45d343101ee/novartis-showcases-significant-data-updates-from-kisqali-r-iptacopan-and-scemblix-r-at-sabcs-and-ash 2023-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0e0c434b421f5ea7/eptinezumab-demonstrates-sustained-long-term-efficacy-in-treatment-resistant-migraine-patients-over-18-months 2023-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/423ddf6343991231/fda-approves-medtronic-s-minimally-invasive-device-for-hypertension-treatment 2023-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9b842fcb25dc092a/outstanding-12-month-first-in-human-data-from-xeltis-axess 2023-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/17e72320a2bcb2f6/uk-approves-world-s-first-crispr-gene-therapy-for-sickle-cell-disease-and-b-thalassemia 2023-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d49b009b6b17491a/biocon-biologics-secures-uk-approval-for-aflibercept-biosimilar-yesafili-expanding-european-market-access 2023-11-15T10:53:21+00:00 weekly 0.7 https://trial.medpath.com/news/c7179bdb4bfa4730/gene-editing-therapy-shows-promise-for-cholesterol-reduction-in-early-trial 2023-11-15T10:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/9a86c6310016420b/novartis-secures-world-first-nhs-partnership-for-inclisiran-population-health-management 2023-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/faf27796e6ee3362/nimmune-biopharma-presents-positive-first-in-human-data-of-nim-1324-at-acr-convergence-2023 2023-11-14T13:16:10+00:00 weekly 0.7 https://trial.medpath.com/news/24dc41a9b567c27d/elafibranor-shows-significant-efficacy-in-phase-iii-trial-for-primary-biliary-cholangitis 2023-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6f9723ea63f064bb/novartis-presents-new-data-on-safety-and-efficacy-of-zolgensma-in-older-and-heavier-children-with-sma 2023-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2742288ec3d3d20f/novartis-and-mmv-develop-novel-malaria-treatment-for-infants-under-5kg-addressing-critical-treatment-gap 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6e0d3d1bf4f80461/padcev-and-keytruda-double-bladder-cancer-survival 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e0a7a0ee64bed7d2/ftc-challenges-over-100-drug-delivery-device-patents-in-orange-book-enforcement-action 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/51f29c10e0046377/pipeline-moves-prospects-drop-after-phase-iii-ovarian-cancer-trial 2023-11-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d5afc9c1e17ef7bd/novartis-ianalumab-achieves-primary-endpoint-in-phase-iii-itp-trial-offering-potential-for-extended-treatment-free-periods 2023-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c855bb55b764a359/novartis-ianalumab-becomes-first-targeted-therapy-to-show-efficacy-in-sjogren-s-disease-phase-iii-trials 2023-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/197a868efc653f0c/experimental-rna-drug-zilebesiran-delivers-six-month-blood-pressure-control-with-single-injection 2023-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c8d04c86608cd35b/in-lung-cancer-j-j-data-amount-to-latest-salvo-against-astrazeneca 2023-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a432882d0e492ff0/fda-approves-takeda-s-adzynma-as-first-treatment-for-ultra-rare-blood-clotting-disorder-cttp 2023-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/58cfc75f46afebaa/fda-approves-leqvio-as-first-line-monotherapy-for-cholesterol-management 2023-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4c51fcf30c9a4c08/fda-approves-new-version-of-diabetes-drug-mounjaro-for 2023-11-08T17:59:27+00:00 weekly 0.7 https://trial.medpath.com/news/89c68febdb680748/chinese-base-editing-therapy-achieves-first-clinical-cure-of-beta-thalassaemia 2023-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c7761c05ad1bd343/acelyrin-inc-slrn-reports-q3-2023-financial-results-key-clinical-trials-progressing 2023-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/040b6edfaa5e2fa7/participant-engagement-and-adherence-to-providing 2023-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3d00d5db842cacf1/what-to-know-about-biosimilar-for-stelara-that-can-treat-psorasis 2023-11-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7db8298795a99c15/learnings-from-real-world-evidence-of-faricimab-in-namd-and-dme-part-1 2023-11-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f0e69ce6a5ab106a/novartis-cosentyx-fails-to-meet-primary-endpoint-in-phase-iii-giant-cell-arteritis-trial 2023-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8a1ef7ca47b59a20/insilico-medicine-pioneers-ai-driven-drug-discovery-with-multimodal-transformers-and-robotic-labs 2023-11-03T06:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/ab4345f73ce779e1/lexeo-therapeutics-launches-100m-ipo-to-advance-gene-therapy-pipeline 2023-11-03T02:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/7e3d00b9bcd67076/ascentage-pharma-s-lisaftoclax-receives-fda-clearance-for-global-phase-iii-trial-in-cll-sll 2023-11-03T01:17:45+00:00 weekly 0.7 https://trial.medpath.com/news/1686f021038138e5/blood-cancer-treatment-breakthrough 2023-11-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3b36f7f2e0fe9e10/eledon-s-tegoprubart-shows-promise-in-phase-1b-kidney-transplant-trial-with-superior-organ-function-preservation 2023-11-02T13:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/26cfe37f013bcfe6/gsk-s-arexvy-dominates-rsv-vaccine-market-with-1-2b-projected-sales-outpacing-pfizer-s-abrysvo 2023-11-02T01:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/e7648c0570522928/novartis-advances-pediatric-asciminib-trial-for-chronic-myeloid-leukemia-with-novel-dosing-strategy 2023-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/122807ed58ae3f6a/kisqali-shows-enhanced-efficacy-in-younger-breast-cancer-patients-with-33-risk-reduction 2023-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9e67e6dddb3bf32c/acurx-pharmaceuticals-stock-is-plummeting-after-biotech-benzinga 2023-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a459d5173d64fffc/alfasigma-acquires-galapagos-jak-inhibitor-jyseleca-in-eur170-million-deal 2023-11-01T00:48:28+00:00 weekly 0.7 https://trial.medpath.com/news/8e640b042d8e3804/endpoints-for-clinical-trials-in-ophthalmology 2023-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/25185a8dcfa65174/doxycycline-postexposure-prophylaxis-for-prevention 2023-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8d96c271eef9bd1f/fda-approves-voquezna-r-vonoprazan-tablets-for-erosive-gerd-treatment 2023-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4bcf8bd56e10e7db/efficacy-and-safety-of-teprotumumab-in-patients-with-thyroid-eye-disease 2023-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e10ba01e134e4ac3/fda-approves-novartis-cosentyx-r-as-the-first-new-biologic-treatment-option-for-hidradenitis-suppurativa-patients-in-nearly-a-decade 2023-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/67e63cf95302e59c/sarepta-srpt-to-seek-approval-for-dmd-therapy-even-after-drug-trial-failed-bloomberg 2023-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3078ba9768a4690c/novel-protac-vepdegestrant-shows-promise-for-esr1-mutant-breast-cancer-in-phase-2-trial 2023-10-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0c29e28dfa64b69b/edgewise-therapeutics-expands-edg-5506-clinical-program-with-new-duchenne-trial-for-gene-therapy-recipients 2023-10-27T16:47:05+00:00 weekly 0.7 https://trial.medpath.com/news/1ccfb173bd7ffab2/4sc-s-resminostat-receives-orphan-drug-designation-from-the-european 2023-10-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/68e1aee28b3dd9be/fda-approves-mirikizumab-omvoh-for-ulcerative-colitis 2023-10-26T22:58:10+00:00 weekly 0.7 https://trial.medpath.com/news/0822cf9db84150cf/eisai-plans-to-submit-bla-for-subcutaneous-lecanemab-following-promising-results 2023-10-26T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5d68f7133e1f6fc0/phase-3-trial-supports-amivantamab-plus-lazertinib-over 2023-10-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0486cbde0e0be70b/us-fda-approves-santhera-s-drug-for-rare-muscular-dystrophy 2023-10-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0e4b58051464f341/ai-and-biomarkers-drive-precision-medicine-evolution-industry-experts-predict-54b-gene-therapy-market-by-2029 2023-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1c7381b2a580e7be/perioperative-durvalumab-plus-chemotherapy-significantly-improves-outcomes-in-resectable-non-small-cell-lung-cancer 2023-10-23T12:46:11+00:00 weekly 0.7 https://trial.medpath.com/news/054dc2cc45cc7ca7/nervgen-pharma-receives-fast-track-designation-for-nvg-291-in-spinal-cord-injury-treatment 2023-10-23T12:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/3b45062e0059cf36/dostarlimab-shows-superior-survival-outcomes-across-multiple-endometrial-cancer-molecular-subgroups-in-phase-3-ruby-trial 2023-10-23T01:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/f2b7954d8ca84f24/verve-therapeutics-announces-clearance-of-investigational-new-drug-application-by-the-u-s-fda-for-verve-101-in-patients-with-heterozygous-familial-hypercholesterolemia 2023-10-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5dc958a6ada48f5b/novartis-pluvictotm-shows-clinically-meaningful-and-highly 2023-10-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8948efb5198e08ed/novel-bispecific-immunotherapy-shows-promise-across-multiple-cancer-types-in-early-clinical-trial 2023-10-19T15:13:10+00:00 weekly 0.7 https://trial.medpath.com/news/ea2484b7c72db067/merck-and-daiichi-sankyo-form-22-billion-alliance-for-three-novel-antibody-drug-conjugates 2023-10-19T04:41:08+00:00 weekly 0.7 https://trial.medpath.com/news/387f4ce97980e708/sequana-medical-reports-positive-long-term-data-for-alfapump-in-treating-ascites 2023-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c0acf1f46edb40e1/cilta-cel-leads-to-high-pfs-rates-in-patients-with-multiple-myeloma 2023-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6a8348d3da0b20e8/fda-clears-rise-therapeutics-ind-application-to-initiate-a-phase-1 2023-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e5ee011b0dab767e/traverse-biotech-has-been-awarded-a-phase-i-sbir-grant-from-the-national-cancer-institute-to-develop-targeted-immunotherapy-for-selected-solid-tumors-biospace 2023-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/384eb38529e4ffe4/bimzelx-r-approved-by-the-u-s-fda-for-the-treatment-of-adults-with 2023-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/073954b489a9d423/fda-grants-seastar-medical-s-selective-cytopheretic-device-breakthrough-device-designation-for-hepatorenal-syndrome 2023-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5efcc08fd6bbd6aa/fda-s-new-real-world-data-guidance-streamlining-drug-development-and-regulatory-approval 2023-10-17T14:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/052a80c5df9ce34e/nucleus-radiopharma-secures-56m-series-a-to-expand-radiopharmaceutical-manufacturing-network 2023-10-17T10:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/738f0e45a11dd480/abbott-receives-fda-clearance-of-tactiflextm-ablation 2023-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1b9645e512cd0290/concept-medical-received-fda-ide-approval-for 2023-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/93117ce7e5eb0961/nhs-to-offer-new-curative-treatment-for-aggressive-blood-cancer 2023-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e9612f537939ca8d/sillajen-presents-clinical-study-overview-of-anticancer-drug-bal0891-at-international-symposium 2023-10-16T16:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/ed3ce62c51a75a07/immix-biopharma-completes-3rd-nxc-201-engineering-batch-at-its-u-s-car-t-manufacturing-site-markets-insider 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b40c53144be8e8e9/advances-in-mrna-based-cancer-vaccines 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/28e37020ef7347e8/tilray-medical-supports-new-clinical-trial-to-study-medical-cannabis-in-glioblastoma-cancer-treatment 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7befbf2163b6243d/spectral-medical-announces-opening-of-tigris-clinical-trial-site-at-the-mayo-clinic-markets-insider 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9ae3c3b155b72ae0/adjuvant-nivolumab-shows-significant-benefit-in-resected-stage-iib-c-melanoma 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b1b4ce1ce3513c07/impact-of-ventilation-strategies-on-pulmonary-and-cardiovascular 2023-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d4fb59a746ba3062/brain-tumor-center-stanford-medicine 2023-10-12T12:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/d6cbd24847af42fd/cap-1002-parent-project-muscular-dystrophy 2023-10-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/143a32033594f7ac/intranasal-epinephrine-spray-shows-superior-pharmacokinetics-to-autoinjector-in-anaphylaxis-treatment-study 2023-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fb39c987e68249d2/south-korea-positions-life-sciences-sector-for-global-leadership-with-strategic-five-point-plan 2023-10-10T21:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/55d99a146ab9f690/crinecerfont-shows-promise-in-treating-children-with-congenital-adrenal-hyperplasia 2023-10-10T16:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/5bfc8d982fb85d94/cuba-advances-phase-iii-clinical-trial-of-jusvinza-for-rheumatoid-arthritis-treatment 2023-10-09T15:25:05+00:00 weekly 0.7 https://trial.medpath.com/news/28e744bb445f9466/analysis-of-sodium-phenylbutyrate-and-taurursodiol 2023-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7aa379ccc5c01f28/rg6501-shows-rapid-improvement-in-retinal-structure-for-geographic-atrophy-patients 2023-10-08T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8998ff08fa1b65a4/paradigm-and-bristol-myers-squibb-collaborate-to-build-a-new-model-for-clinical-trials 2023-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f58ba44d375b812c/fda-panel-votes-sufficient-evidence-available-to-support 2023-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2a11aa50cadf16dc/landmark-uk-biobank-study-reveals-14000-novel-gene-protein-interactions-to-transform-drug-discovery 2023-10-05T02:20:26+00:00 weekly 0.7 https://trial.medpath.com/news/2c16bf0ad68f417e/expanded-access-programs-bridging-the-gap-between-clinical-trials-and-patient-need 2023-10-04T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8f7a2b8661530dcf/ozempic-wegovy-improve-blood-sugar-control-and-weight-loss-over-3-years-study-finds 2023-10-03T14:38:13+00:00 weekly 0.7 https://trial.medpath.com/news/37eb321c104a5da6/eli-lilly-acquires-point-biopharma-for-1-4-billion-to-expand-radioligand-therapy-portfolio 2023-10-03T05:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/5133d7a61653de09/novavax-2023-2024-covid-19-vaccine-authorized-for-emergency-use-in-the-u-s 2023-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e83758718a6683b2/valbiotis-sa-phase-ii-iii-reverse-it-study-to-be-presented-at-2023-easd-congress 2023-10-02T17:42:02+00:00 weekly 0.7 https://trial.medpath.com/news/dd1b2731080e0814/fda-greenlights-alzamend-neuro-s-phase-iia-trial-of-novel-lithium-therapy-al001-for-bipolar-disorder 2023-10-02T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9ff987c5d3934bba/pipeline-moves-advancement-prospects-plunge-for-parkinsons 2023-10-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4a140e88a88a6f9f/car-t-cell-therapies-for-diffuse-midline-glioma-sciencedirect 2023-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7b80be7c443f809c/advancements-in-immune-checkpoint-inhibition-for-hepatocellular-carcinoma-treatment 2023-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8daa47f14d6636c9/nxc-201-demonstrates-feasibility-of-bcma-directed-car-t-cell-therapy-in-relapsed-refractory-al-amyloidosis 2023-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8b49cf56490e693e/fda-approves-exxua-a-novel-antidepressant-for-major-depressive-disorder 2023-09-28T09:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/6f2f144c1650d0c1/fda-revokes-emergency-use-authorization-for-evusheld 2023-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e757539325e7405e/j-j-cancer-drug-combo-beats-tagrisso-in-closely-watched-trial 2023-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e893f84da1810ba1/akebia-therapeutics-resubmits-new-drug-application-to-the-fda-for-vadadustat 2023-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a880e52908031995/fda-approves-bosutinib-for-pediatric-chronic-myelogenous-leukemia-patients 2023-09-27T18:39:45+00:00 weekly 0.7 https://trial.medpath.com/news/72cbea9b9f6e0fe9/unity-biotechnology-announces-48-week-results-from-phase-2-envision-study-of-ubx1325-in-patients-with-wet-age-related-macular-degeneration 2023-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0df43098783c5b88/viva-s-portfolio-companies-announce-significant-advances-in-biopharmaceutical-innovations 2023-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b731f7c3f1b05ffe/amphista-therapeutics-hits-second-milestone-in-bristol-myers-squibb-protein-degradation-partnership 2023-09-26T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/4bdf24f8de3b0e56/actinogen-optimizes-xanamia-phase-2b-alzheimer-s-disease-trial-design 2023-09-26T12:56:06+00:00 weekly 0.7 https://trial.medpath.com/news/20d02ff0abed7d66/4sc-receives-orphan-drug-designation-odd-for-resminostat-kinselby 2023-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c84c49f7eb61caa8/xeltis-starts-the-pivotal-clinical-trial-for-axess 2023-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ca00b9d3b800e7c7/novel-targets-and-strategic-sequencing-the-evolving-landscape-of-t-cell-redirection-therapies-in-multiple-myeloma 2023-09-22T13:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/9c23fb0de070942d/ai-powered-hasten-tool-accelerates-virtual-drug-screening-10-fold 2023-09-22T02:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/2e65c30c2a48f2ca/leucid-bio-s-lateral-nkg2d-car-t-therapy-leu011-receives-mhra-approval-for-solid-tumor-clinical-trial 2023-09-21T03:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/2ff9c1dd09b25805/u-s-food-and-drug-administration-approves-orphan-drug-designation-for-immix-biopharma-nxc-201-as-a-treatment-for-amyloid-light-chain-al-amyloidosis-september-21-2023-at-08-56-am-edt-marketscreener 2023-09-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6bb7e62e421dbb8a/drug-for-rare-kidney-disease-narrowly-misses-mark-in-clinical-trial 2023-09-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7ef7fc50a56d84c0/first-roactemra-biosimilar-tyenne-receives-eu-approval-marking-milestone-for-fresenius-kabi 2023-09-20T02:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/ff4302be7e23b634/elon-musks-neuralink-recruiting-humans-to-trial-brain-implant 2023-09-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/91349f0d4f768419/extended-course-nirmatrelvir-ritonavir-shows-promise-in-treating-long-covid-symptoms 2023-09-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/90b0d304f95fe845/translarna-approval-for-dmd-in-eu-not-recommended-for-renewal-therapy-developer-ptc-to-seek-new-review-by-ema-committee-muscular-dystrophy-news 2023-09-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6ee35dfc0619c3d9/cloud-based-data-analytics-emerges-as-key-driver-for-life-sciences-innovation-and-drug-development 2023-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2c11159822b881af/genetically-modified-pig-kidney-functions-for-61-days-in-human-body-setting-xenotransplantation-record 2023-09-14T15:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/f4c9cbb8aa077e5c/anavex-s-phase-2b-3-trial-of-blarcamesine-shows-promising-results-in-alzheimer-s-disease-treatment 2023-09-14T11:30:11+00:00 weekly 0.7 https://trial.medpath.com/news/0365a16ffa196bc8/game-changing-alzheimer-s-drugs-could-drive-a-wave-of 2023-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b8ea39c7224ef6f6/axicabtagene-ciloleucel-as-second-line-therapy-in-large-b-cell-lymphoma 2023-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d12b31b1ab85335e/moderna-s-combo-covid-19-and-flu-vaccine-shows-promising-results-in-early-trial 2023-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fb5459f1f2a1f87c/pharma-stock-plummets-on-skin-disease-trial-schaeffer-s-investment-research 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fa7eb402090aa539/izokibep-fails-in-phase-2b-3-hidradenitis-suppurativa-trial 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5d29fb83badcf8b5/acelyrin-nasdaq-slrn-plummets-on-disappointing-hs-trial-results-tipranks-com 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/89af945108daef56/abbvie-s-skyrizi-r-risankizumab-met-all-primary-and-secondary-endpoints-versus-stelara-r-ustekinumab-in-head-to-head-study-in-crohn-s-disease 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4bbade28c8f1f379/fda-approves-updated-covid-vaccines-from-pfizer-and-moderna-as 2023-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b36a926c31313985/advances-in-alzheimer-s-disease-treatment-a-focus-on-disease-modifying-therapies 2023-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ed15a84c9a661f0e/vir-biotech-faces-steep-decline-bank-of-america-warns 2023-09-08T14:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/11d07924c271489f/ariceum-therapeutics-doses-first-patient-in-phase-ib-study-for-small-cell-lung-cancer-treatment 2023-09-07T08:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/5c9673a88c1f3972/application-to-market-givinostat-for-dmd-in-europe-under 2023-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bd8cb0e7dfff4519/spectral-medical-inc-closes-c-6-1-million-bought-deal-convertible-note-financing-the-globe-and-mail 2023-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ec260209184ca2e4/retail-pharmacies-are-working-with-pharmaceutical-companies-to 2023-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f477724bfc46a3d4/bispecific-t-cell-engagers-show-promise-as-later-line-therapies-for-relapsed-refractory-dlbcl 2023-09-06T19:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/f9816a2cae1c7f8d/olema-oncology-secures-up-to-180-million-in-combined-financing 2023-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f5ca788481691362/first-patient-dosed-in-phase-2-activate-trial-of-bia-28-6156-for 2023-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/69047d1231bc42b2/cingulate-s-phase-3-trial-shows-promising-results-for-once-daily-adhd-treatment-ctx-1301 2023-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/38696834b58946ac/nestle-divests-palforzia-to-stallergenes-greer-exits-peanut-allergy-treatment-market 2023-09-04T02:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/6a091a5a45e8cd67/mpn-628-surpass-et-ropeginterferon-alfa-2b-p1101 2023-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/041cc30f43e087d7/denosumab-biosimilar-ly01011-demonstrates-bioequivalence-in-phase-1-trial 2023-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ffeb3cd93811a76c/intraventricular-b7-h3-car-t-cells-for-diffuse-intrinsic 2023-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9faa071236ce2cac/pfizer-launches-phase-3-trial-testing-elranatamab-triple-combination-for-newly-diagnosed-multiple-myeloma 2023-08-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5f7e6ae2e92382d9/fda-rejects-outlook-therapeutics-wet-amd-drug-due-to-manufacturing-issues-and-insufficient-clinical-evidence 2023-08-30T13:17:56+00:00 weekly 0.7